Envision Healthcare Inactive 10-Q13 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 11, 2013
Document and Entity Information	'	'
Entity Registrant Name	'Envision Healthcare Holdings, Inc.	'
Entity Central Index Key	'0001578318	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'No	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	180,382,885
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue, net of contractual discounts	$1,691,208	$1,529,140	$4,986,261	$4,381,061
Provision for uncompensated care	-735,320	-708,329	-2,242,794	-1,952,858
Net revenue	955,888	820,811	2,743,467	2,428,203
Compensation and benefits	677,797	577,502	1,963,546	1,706,205
Operating expenses	110,387	100,617	313,145	305,005
Insurance expense	26,974	22,907	78,647	75,352
Selling, general and administrative expenses	40,733	18,541	86,521	57,670
Depreciation and amortization expense	35,175	30,592	104,552	91,844
Restructuring charges	1,319	2,028	4,988	10,751
Income from operations	63,503	68,624	192,068	181,376
Interest income from restricted assets	2	-116	634	429
Interest expense	-46,772	-41,322	-148,526	-126,288
Realized gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	-29,519	-1,561	-29,641	-6,733
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	-12,680	26,567	1,789	50,490
Income tax benefit (expense)	4,949	-11,448	-3,932	-21,952
(Loss) income before equity in earnings of unconsolidated subsidiary	-7,731	15,119	-2,143	28,538
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	-7,663	15,209	-1,913	28,842
Other comprehensive (loss) income, net of tax:	'	'	'	'
Unrealized holding (losses) gains during the period	-133	471	-582	674
Unrealized gains (losses) on derivative financial instruments	236	1,031	-42	-234
Comprehensive (loss) income	($7,560)	$16,711	($2,537)	$29,282
Basic net (loss) income per common share (in dollars per share)	($0.05)	$0.12	($0.01)	$0.22
Diluted net (loss) income per common share (in dollars per share)	($0.05)	$0.11	($0.01)	$0.22
Average common shares outstanding, basic (in shares)	157,282,885	130,230,634	139,969,940	130,219,651
Average common shares outstanding, diluted (in shares)	157,282,885	133,463,882	139,969,940	132,479,821

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	$575,761	$37,032	$57,832	$128,428	$124,198	$134,023
Insurance collateral	29,039	'	24,481	'	'	'
Trade and other accounts receivable, net	750,484	'	625,144	'	'	'
Parts and supplies inventory	22,539	'	22,050	'	'	'
Prepaids and other current assets	31,277	'	23,752	'	'	'
Total current assets	1,409,100	'	753,259	'	'	'
Non-current assets:	'	'	'	'	'	'
Property, plant and equipment, net	190,837	'	191,864	'	'	'
Intangible assets, net	524,317	'	564,218	'	'	'
Insurance collateral	12,107	'	20,760	'	'	'
Goodwill	2,437,620	'	2,413,632	'	'	'
Other long-term assets	75,969	'	93,100	'	'	'
Total assets	4,649,950	'	4,036,833	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	65,358	'	53,909	'	'	'
Accrued liabilities	352,604	'	388,935	'	'	'
Current deferred tax liabilities	28,226	'	23,568	'	'	'
Current portion of long-term debt	12,316	'	12,282	'	'	'
Total current liabilities	458,504	'	478,694	'	'	'
Long-term debt	2,225,407	'	2,647,098	'	'	'
Long-term deferred tax liabilities	156,761	'	156,761	'	'	'
Insurance reserves and other long-term liabilities	212,176	'	209,593	'	'	'
Total liabilities	3,052,848	'	3,492,146	'	'	'
Equity:	'	'	'	'	'	'
Common stock ($0.01 par value; 2,000,000,000 shares authorized, 180,382,885 and 130,661,627 issued and outstanding as of September 30, 2013 and December 31, 2012, respectively)	1,804	'	1,307	'	'	'
Additional paid-in capital	1,580,519	'	525,098	'	'	'
Treasury stock at cost	-1,347	'	-381	'	'	'
Retained earnings	10,433	'	12,346	'	'	'
Accumulated other comprehensive loss	-837	'	-213	'	'	'
Total stockholders' equity	1,590,572	'	538,157	'	'	'
Noncontrolling interest	6,530	'	6,530	'	'	'
Total equity	1,597,102	'	544,687	'	'	'
Total liabilities and equity	$4,649,950	'	$4,036,833	'	'	'

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	180,382,885	130,661,627
Common stock, shares outstanding	180,382,885	130,661,627

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
Cash Flows from Operating Activities	'	'	'
Net (loss) income	($7,663)	($1,913)	$28,842
Adjustments to reconcile net (loss) income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	39,684	118,683	104,207
Gain on disposal of property, plant and equipment	-45	-55	-272
Equity-based compensation expense	1,062	3,186	3,186
Excess tax benefits from equity-based compensation	'	-3,168	'
Loss on early debt extinguishment	29,519	29,641	6,733
Equity in earnings of unconsolidated subsidiary	-68	-230	-304
Dividends received	'	-556	611
Deferred income taxes	88	4,319	43,146
Payment of dissenting shareholder settlement	'	-13,717	'
Changes in operating assets/liabilities, net of acquisitions:	'	'	'
Trade and other accounts receivable	-71,543	-126,506	-68,376
Parts and supplies inventory	-335	-489	351
Prepaids and other current assets	3,308	-8,997	-6,701
Accounts payable and accrued liabilities	32,468	22,520	60,139
Insurance accruals	5,247	1,795	-2,315
Net cash provided by operating activities	31,722	25,625	169,247
Cash Flows from Investing Activities	'	'	'
Purchases of property, plant and equipment	-19,295	-45,493	-44,311
Proceeds from sale of property, plant and equipment	68	396	7,092
Acquisition of businesses, net of cash received	-25,935	-27,358	-20,559
Net change in insurance collateral	3,282	2,880	90,601
Other investing activities	-404	-456	589
Net cash (used in) provided by investing activities	-42,284	-70,031	33,412
Cash Flows from Financing Activities	'	'	'
Envision Healthcare Corporation issuance of common stock	1,110,900	1,112,017	'
Borrowings under senior secured term loan facility	'	150,000	'
Repayments under ABL credit facility	-27,500	-125,000	'
Repayments of ABL Facility and other debt	-3,339	-10,383	-225,616
Repayment of bonds	-450,000	-450,000	'
Equity issuance costs	-62,020	-63,420	'
Debt issue costs	'	-5,011	-95
Payment of premiums for debt extinguishment	-12,386	-12,386	-528
Excess tax benefits from stock-based compensation	'	3,168	'
Receipts from non-controlling interest	'	'	6,530
Payment of dissenting shareholder settlement	'	-38,336	'
Net change in bank overdrafts	-6,364	1,686	11,455
Net cash provided by (used in) financing activities	549,291	562,335	-208,254
Change in cash and cash equivalents	538,729	517,929	-5,595
Cash and cash equivalents, beginning of period	37,032	57,832	134,023
Cash and cash equivalents, end of period	$575,761	$575,761	$128,428

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (ENVISION HEALTHCARE CORPORATION) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue, net of contractual discounts	$1,691,208	$1,529,140	$4,986,261	$4,381,061
Provision for uncompensated care	-735,320	-708,329	-2,242,794	-1,952,858
Net revenue	955,888	820,811	2,743,467	2,428,203
Compensation and benefits	677,797	577,502	1,963,546	1,706,205
Operating expenses	110,387	100,617	313,145	305,005
Insurance expense	26,974	22,907	78,647	75,352
Selling, general and administrative expenses	40,733	18,541	86,521	57,670
Depreciation and amortization expense	35,175	30,592	104,552	91,844
Restructuring charges	1,319	2,028	4,988	10,751
Income from operations	63,503	68,624	192,068	181,376
Interest income from restricted assets	2	-116	634	429
Interest expense	-46,772	-41,322	-148,526	-126,288
Realized gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	-29,519	-1,561	-29,641	-6,733
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	-12,680	26,567	1,789	50,490
Income tax benefit (expense)	4,949	-11,448	-3,932	-21,952
(Loss) income before equity in earnings of unconsolidated subsidiary	-7,731	15,119	-2,143	28,538
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	-7,663	15,209	-1,913	28,842
Other comprehensive income (loss), net of tax:	'	'	'	'
Unrealized holding (losses) gains during the period	-133	471	-582	674
Unrealized gains (losses) on derivative financial instruments	236	1,031	-42	-234
Comprehensive (loss) income	-7,560	16,711	-2,537	29,282
Corporation	'	'	'	'
Revenue, net of contractual discounts	1,691,208	1,529,140	4,986,261	4,381,061
Provision for uncompensated care	-735,320	-708,329	-2,242,794	-1,952,858
Net revenue	955,888	820,811	2,743,467	2,428,203
Compensation and benefits	677,797	577,502	1,963,546	1,706,205
Operating expenses	110,404	100,617	313,075	305,005
Insurance expense	26,974	22,907	78,647	75,352
Selling, general and administrative expenses	40,731	18,541	86,518	57,670
Depreciation and amortization expense	35,175	30,592	104,552	91,844
Restructuring charges	1,319	2,028	4,988	10,751
Income from operations	63,488	68,624	192,141	181,376
Interest income from restricted assets	2	-116	634	429
Interest expense	-39,131	-41,322	-117,959	-126,288
Realized gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	'	-1,561	-122	-6,733
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	24,465	26,567	61,948	50,490
Income tax benefit (expense)	-9,816	-11,448	-27,782	-21,952
(Loss) income before equity in earnings of unconsolidated subsidiary	14,649	15,119	34,166	28,538
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	14,717	15,209	34,396	28,842
Other comprehensive income (loss), net of tax:	'	'	'	'
Unrealized holding (losses) gains during the period	-133	471	-582	674
Unrealized gains (losses) on derivative financial instruments	236	1,031	-42	-234
Comprehensive (loss) income	$14,820	$16,711	$33,772	$29,282

CONSOLIDATED_BALANCE_SHEETS_EN

CONSOLIDATED BALANCE SHEETS (ENVISION HEALTHCARE CORPORATION) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	$575,761	$37,032	$57,832	$128,428	$124,198	$134,023
Insurance collateral	29,039	'	24,481	'	'	'
Trade and other accounts receivable, net	750,484	'	625,144	'	'	'
Parts and supplies inventory	22,539	'	22,050	'	'	'
Prepaids and other current assets	31,277	'	23,752	'	'	'
Total current assets	1,409,100	'	753,259	'	'	'
Non-current assets:	'	'	'	'	'	'
Property, plant and equipment, net	190,837	'	191,864	'	'	'
Intangible assets, net	524,317	'	564,218	'	'	'
Insurance collateral	12,107	'	20,760	'	'	'
Goodwill	2,437,620	'	2,413,632	'	'	'
Other long-term assets	75,969	'	93,100	'	'	'
Total assets	4,649,950	'	4,036,833	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	65,358	'	53,909	'	'	'
Accrued liabilities	352,604	'	388,935	'	'	'
Current deferred tax liabilities	28,226	'	23,568	'	'	'
Current portion of long-term debt	12,316	'	12,282	'	'	'
Total current liabilities	458,504	'	478,694	'	'	'
Long-term debt	2,225,407	'	2,647,098	'	'	'
Long-term deferred tax liabilities	156,761	'	156,761	'	'	'
Insurance reserves and other long-term liabilities	212,176	'	209,593	'	'	'
Total liabilities	3,052,848	'	3,492,146	'	'	'
Equity:	'	'	'	'	'	'
Common stock ($0.01 par value; 1,000 shares authorized, issued and outstanding as of September 30, 2013 and December 31, 2012)	1,804	'	1,307	'	'	'
Additional paid-in capital	1,580,519	'	525,098	'	'	'
Treasury stock at cost	-1,347	'	-381	'	'	'
Retained earnings	10,433	'	12,346	'	'	'
Accumulated other comprehensive loss	-837	'	-213	'	'	'
Total stockholders' equity	1,590,572	'	538,157	'	'	'
Noncontrolling interest	6,530	'	6,530	'	'	'
Total equity	1,597,102	'	544,687	'	'	'
Total liabilities and equity	4,649,950	'	4,036,833	'	'	'
Corporation	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	94,039	36,752	57,551	128,428	124,198	134,023
Insurance collateral	29,039	'	24,481	'	'	'
Trade and other accounts receivable, net	750,484	'	625,413	'	'	'
Parts and supplies inventory	22,539	'	22,050	'	'	'
Prepaids and other current assets	28,403	'	23,514	'	'	'
Total current assets	924,504	'	753,009	'	'	'
Non-current assets:	'	'	'	'	'	'
Property, plant and equipment, net	190,837	'	191,864	'	'	'
Intangible assets, net	524,317	'	564,218	'	'	'
Insurance collateral	12,107	'	20,760	'	'	'
Goodwill	2,437,620	'	2,413,632	'	'	'
Other long-term assets	75,969	'	85,857	'	'	'
Total assets	4,165,354	'	4,029,340	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	65,241	'	53,792	'	'	'
Accrued liabilities	382,718	'	387,430	'	'	'
Current deferred tax liabilities	28,226	'	23,568	'	'	'
Current portion of long-term debt	12,316	'	12,282	'	'	'
Total current liabilities	488,501	'	477,072	'	'	'
Long-term debt	2,225,407	'	2,209,923	'	'	'
Long-term deferred tax liabilities	156,850	'	156,850	'	'	'
Insurance reserves and other long-term liabilities	212,176	'	209,593	'	'	'
Total liabilities	3,082,934	'	3,053,438	'	'	'
Equity:	'	'	'	'	'	'
Common stock ($0.01 par value; 1,000 shares authorized, issued and outstanding as of September 30, 2013 and December 31, 2012)	'	'	'	'	'	'
Additional paid-in capital	1,003,013	'	908,488	'	'	'
Treasury stock at cost	-1,347	'	-381	'	'	'
Retained earnings	75,061	'	61,478	'	'	'
Accumulated other comprehensive loss	-837	'	-213	'	'	'
Total stockholders' equity	1,075,890	'	969,372	'	'	'
Noncontrolling interest	6,530	'	6,530	'	'	'
Total equity	1,082,420	'	975,902	'	'	'
Total liabilities and equity	$4,165,354	'	$4,029,340	'	'	'

CONSOLIDATED_BALANCE_SHEETS_Pa1

CONSOLIDATED BALANCE SHEETS (Parenthetical) (ENVISION HEALTHCARE CORPORATION) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	180,382,885	130,661,627
Common stock, shares outstanding	180,382,885	130,661,627
Corporation	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	1,000	1,000
Common stock, shares issued	1,000	1,000
Common stock, shares outstanding	1,000	1,000

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (ENVISION HEALTHCARE CORPORATION) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Cash Flows from Operating Activities	'	'	'	'
Net income	($7,663)	$15,209	($1,913)	$28,842
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	39,684	34,584	118,683	104,207
Gain on disposal of property, plant and equipment	-45	-208	-55	-272
Equity-based compensation expense	1,062	1,062	3,186	3,186
Excess tax benefits from equity-based compensation	'	'	-3,168	'
Loss on early debt extinguishment	29,519	1,561	29,641	6,733
Equity in earnings of unconsolidated subsidiary	-68	-90	-230	-304
Dividends received	'	'	-556	611
Deferred income taxes	88	42,939	4,319	43,146
Payment of dissenting shareholder settlement	'	'	-13,717	'
Changes in operating assets/liabilities, net of acquisitions:	'	'	'	'
Trade and other accounts receivable	-71,543	-25,547	-126,506	-68,376
Parts and supplies inventory	-335	-37	-489	351
Prepaids and other current assets	3,308	-164	-8,997	-6,701
Accounts payable and accrued liabilities	32,468	33,933	22,520	60,139
Insurance accruals	5,247	2,874	1,795	-2,315
Net cash provided by operating activities	31,722	106,116	25,625	169,247
Cash Flows from Investing Activities	'	'	'	'
Purchases of property, plant and equipment	-19,295	-19,126	-45,493	-44,311
Proceeds from sale of property, plant and equipment	68	5,641	396	7,092
Acquisition of businesses, net of cash received	-25,935	-19,259	-27,358	-20,559
Net change in insurance collateral	3,282	-17,773	2,880	90,601
Other investing activities	-404	2,885	-456	589
Net cash (used in) provided by investing activities	-42,284	-47,632	-70,031	33,412
Cash Flows from Financing Activities	'	'	'	'
Envision Healthcare Corporation issuance of common stock	1,110,900	'	1,112,017	'
Borrowings under senior secured term loan facility	'	'	150,000	'
Net repayments under ABL credit facility	'	'	-125,000	'
Repayments of senior secured term loan facility and other debt	-3,339	-53,142	-10,383	-225,616
Debt issue costs	'	'	-5,011	-95
Excess tax benefits from stock-based compensation	'	'	3,168	'
Repayment of equity	'	-398	'	'
Receipts from non-controlling interest	'	'	'	6,530
Payment of dissenting shareholder settlement	'	'	-38,336	'
Net change in bank overdrafts	-6,364	-714	1,686	11,455
Net cash provided by (used in) financing activities	549,291	-54,254	562,335	-208,254
Change in cash and cash equivalents	538,729	4,230	517,929	-5,595
Cash and cash equivalents, beginning of period	37,032	124,198	57,832	134,023
Cash and cash equivalents, end of period	575,761	128,428	575,761	128,428
Corporation	'	'	'	'
Cash Flows from Operating Activities	'	'	'	'
Net income	14,717	15,209	34,396	28,842
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	38,979	34,584	115,865	104,207
Gain on disposal of property, plant and equipment	-45	-208	-55	-272
Equity-based compensation expense	1,062	1,062	3,186	3,186
Excess tax benefits from equity-based compensation	'	'	-3,168	'
Loss on early debt extinguishment	'	1,561	122	6,733
Equity in earnings of unconsolidated subsidiary	-68	-90	-230	-304
Dividends received	'	'	-556	611
Deferred income taxes	87	42,939	2,244	43,146
Payment of dissenting shareholder settlement	'	'	-13,717	'
Changes in operating assets/liabilities, net of acquisitions:	'	'	'	'
Trade and other accounts receivable	-69,716	-25,547	-126,237	-68,376
Parts and supplies inventory	-335	-37	-489	351
Prepaids and other current assets	5,081	-164	-4,407	-6,701
Accounts payable and accrued liabilities	55,745	33,933	54,139	60,139
Insurance accruals	5,247	2,874	1,795	-2,315
Net cash provided by operating activities	50,754	106,116	64,000	169,247
Cash Flows from Investing Activities	'	'	'	'
Purchases of property, plant and equipment	-19,295	-19,126	-45,493	-44,311
Proceeds from sale of property, plant and equipment	68	5,641	396	7,092
Acquisition of businesses, net of cash received	-25,935	-19,259	-27,358	-20,559
Net change in insurance collateral	3,282	-17,773	2,880	90,601
Other investing activities	-404	2,885	-456	589
Net cash (used in) provided by investing activities	-42,284	-47,632	-70,031	33,412
Cash Flows from Financing Activities	'	'	'	'
Envision Healthcare Corporation issuance of common stock	'	'	1,117	'
Borrowings under senior secured term loan facility	'	'	150,000	'
Capital contributed by Parent	86,087	'	86,087	'
Net repayments under ABL credit facility	-27,500	'	-125,000	'
Repayments of senior secured term loan facility and other debt	-3,339	-53,142	-10,383	-225,616
Dividend paid	'	'	-20,813	'
Debt issue costs	'	'	-5,007	-95
Excess tax benefits from stock-based compensation	'	'	3,168	'
Repayment of equity	'	-398	'	-528
Receipts from non-controlling interest	'	'	'	6,530
Payment of dissenting shareholder settlement	'	'	-38,336	'
Net change in bank overdrafts	-6,431	-714	1,686	11,455
Net cash provided by (used in) financing activities	48,817	-54,254	42,519	-208,254
Change in cash and cash equivalents	57,287	4,230	36,488	-5,595
Cash and cash equivalents, beginning of period	36,752	124,198	57,551	134,023
Cash and cash equivalents, end of period	$94,039	$128,428	$94,039	$128,428

General

General	9 Months Ended
General	Sep. 30, 2013
General	'
General	'
	1. General

	Basis of Presentation of Financial Statements

	Envision Healthcare Holdings, Inc. (“Holding”) indirectly owns all of the outstanding common stock of Envision Healthcare Corporation (“Corporation”). In June 2013, CDRT Holding Corporation’s name was changed to Envision Healthcare Holdings, Inc. and Emergency Medical Services Corporation’s name was changed to Envision Healthcare Corporation.

	The accompanying interim consolidated financial statements for Holding and Corporation have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim reporting, and accordingly, do not include all of the disclosures required for annual financial statements. In the opinion of management, the consolidated financial statements of Holding and Corporation (together the “Company” or “EVHC”) include all normal recurring adjustments necessary for a fair presentation of the periods presented. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year ending December 31, 2013. For further information on Holding’s significant accounting policies and other information, see Holding’s consolidated financial statements, including the accounting policies and notes thereto for the year ended December 31, 2012, which includes all disclosures required by GAAP, included in the Registration Statement (File No. 333-189292) (“Holding’s Registration Statement”) which was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on August 13, 2013 for an initial public offering of its common stock, par value $0.01 per share (“Common Stock”). See Note 2 for further information on Holding’s initial public offering and its equity. For further information on Corporation’s significant accounting policies and other information, see Corporation’s consolidated financial statements, including the accounting policies and notes thereto for the year ended December 31, 2012, which includes all disclosures required by GAAP, included in Corporation’s Annual Report on Form 10-K for the year ended December 31, 2012.

	On July 29, 2013, Holding effected a 9.3 for 1.0 stock split of Holding’s common stock, resulting in 132,082,885 shares of common stock issued, not including 504,197 treasury shares. The accompanying consolidated financial statements give retroactive effect to the stock split for all periods presented.

	The Company’s business is conducted primarily through two operating subsidiaries, EmCare Holdings, Inc. (“EmCare”), its facility-based physician services segment, and American Medical Response, Inc. (“AMR”), its medical transportation services segment.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2013
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies

	Consolidation

	The consolidated financial statements of Holding include all of its wholly-owned subsidiaries, including Corporation and its respective subsidiaries and affiliated physician groups. The consolidated financial statements of Corporation, include all of its wholly-owned subsidiaries, including EmCare and AMR and their respective subsidiaries, and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.

	Use of Estimates

	The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.

	Insurance

	Insurance collateral is comprised principally of government and investment grade securities and cash deposits with third parties and supports the Company’s insurance program and reserves. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. Insurance collateral also includes a receivable from insurers of $1.3 million and $1.6 million as of September 30, 2013 and December 31, 2012, respectively, for liabilities in excess of our self-insured retention.

	Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first $1 to $3 million of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

	The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims, other than general liability claims, are discounted at a rate of 1.5%. General liability claims are not discounted.

	The Company’s most recent actuarial valuation was completed in September 2013. As a result of this and previous actuarial valuations, the Company recorded increases in its provisions for insurance liabilities of $1.6 million and $1.2 million during the three and nine month periods ended September 30, 2013, respectively, compared to increases of $0.9 million and $0.3 million for three and nine month periods ended September 30, 2012, respectively, related to reserves for losses in prior years.

	The long-term portion of insurance reserves was $192.8 million and $189.4 million as of September 30, 2013 and December 31, 2012, respectively.

	Trade and Other Accounts Receivable, net

	The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee for service charges as of December 31, 2012 was equal to approximately 97% and 93% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances are as follows:

			September 30,			December 31,
			2013			2012
	Gross trade accounts receivable		$	3,570,888		$	3,085,758
	Allowance for contractual discounts		1,826,881			1,619,488
	Allowance for uncompensated care		993,881			841,754
	Net trade accounts receivable		750,126			624,516
	Other receivables, net		358			897
	Net accounts receivable — Corporation		750,484			625,413
	Other receivables, net — adjustment for Holding		—			(269		)
	Net accounts receivable — Holding		$	750,484		$	625,144

	Other receivables primarily represent EmCare hospital subsidies and fees, and AMR fees for stand-by and special events and subsidies from community organizations.

	Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. In addition, a look-back analysis is done, typically after 15 months, to compare actual cash collected on a date of service basis to the revenue recorded for that period. Any adjustment necessary for an overage or deficit in these allowances based on actual collections is recorded through a revenue adjustment in the current period.

	AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated on claim level, historical write-off experience.

	Business Combinations

	Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

	Revenue Recognition

	Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients, for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies and fees at EmCare and fees for stand-by, special event and community subsidies at AMR.

	The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for the costs of the services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within our care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

	Net revenue for the three and nine month periods ended September 30, 2013 and 2012 consisted of the following:

			Three months ended						Nine months ended
			September 30,						September 30,
			2013			2012			2013			2012
	Fee-for-service revenue, net of contractuals:
	Medicare		$	231,042		$	195,111		$	700,823		$	577,311
	Medicaid		51,991			47,723			155,055			141,050
	Commercial insurance and managed care		590,924			541,542			1,719,642			1,559,170
	Self-pay		645,774			611,508			1,964,068			1,703,304
Sub-total		1,519,731			1,395,884			4,539,588			3,980,835
Subsidies and fees		171,477			133,256			446,673			400,226
Revenue, net of contractuals		1,691,208			1,529,140			4,986,261			4,381,061
Provision for uncompensated care		(735,320		)	(708,329		)	(2,242,794		)	(1,952,858		)
Net revenue		$	955,888		$	820,811		$	2,743,467		$	2,428,203

Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate resulted in an increase of $1.1 million and a reduction of $1.6 million to the contractual discount or uncompensated care provisions for the three months ended September 30, 2013 and 2012, respectively, and an increase of $0.2 million and a reduction of $6.3 million to the contractual discount or uncompensated care provisions for the nine months ended September 30, 2013 and 2012, respectively.

The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.

Equity Structure and Initial Public Offering — Holding

On August 13, 2013, Holding’s Registration Statement was declared effective by the SEC for an initial public offering of its Common Stock. Holding registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock, which were sold to the underwriters pursuant to their option to purchase additional shares at a price of $23 per share. On August 19, 2013, Holding completed the offering of 48,300,000 shares of Common Stock, at a price of $23 per share, for an aggregate offering price of $1,110.9 million. At the closing, we received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with Holding and Corporation (“Consulting Agreement”) which was recorded to “Selling, general and administrative expenses” in the Company’s Consolidated Statements of Operation, see Note 12. As of September 30, 2013, approximately $1.6 million of these expenses have not been paid.

Net proceeds from the initial public offering were used to (i) redeem in full Holding’s Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, and (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings. The remaining proceeds will be used for general corporate purposes which may include, among other things, repayment of indebtedness and acquisitions.

Equity Structure — Corporation

On February 13, 2011, Corporation entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Envision Healthcare Intermediate Corporation (“Parent”), formerly known as CDRT Acquisition Corporation, and CDRT Merger Sub, Inc. (“Merger Sub”), formerly a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, Merger Sub merged with and into Corporation, with Corporation as the surviving corporation and a wholly owned subsidiary of Parent on May 25, 2011. Immediately following the Merger, all of the outstanding common stock of Parent was owned by Holding, which is owned by affiliates of CD&R and members of management and directors of Corporation.

Prior to the Merger, Corporation acted as the general partner and majority equity holder of EMS LP, with the balance of the EMS LP equity held by persons affiliated with Corporation’s previous principal equity holder. The EMS LP equity was exchangeable at any time for shares of Corporation’s common stock, and holders of the LP exchangeable units had the right to vote at stockholder meetings with limited exceptions. Accordingly, prior to the Merger, Corporation accounted for the LP exchangeable units as if the LP exchangeable units were shares of its common stock, including reporting the LP exchangeable units in the equity section of Corporation’s balance sheet and including the number of outstanding LP exchangeable units in both its basic and diluted earnings per share calculations.

On May 25, 2011, in connection with the Merger, the equity structure of Holding was altered as follows:

· LP units of the entity formerly known as EMS LP were exchanged for Corporation common stock;

· outstanding shares of Corporation common stock were converted into the right to receive $6.88 per share in cash, without interest and less any applicable withholding taxes;

· options to purchase shares of Corporation common stock (other than options that were rolled over by certain members of management as described below), vested or unvested, were cancelled and each option was converted into the right to receive a cash payment equal to the excess (if any) of $6.88 per share over the exercise price per share of the option times the number of shares subject to the option, without interest and less any applicable withholding taxes;

· restricted shares, vested or unvested, were fully vested at the effective time and canceled and extinguished and each restricted share was converted into the right to receive $6.88 per share in cash, without interest and less any applicable withholding taxes;

· restricted stock units, vested or unvested, were cancelled and extinguished, and each restricted stock unit was converted into the right to receive a cash payment equal to $6.88 per share times the number of shares of Corporation common stock subject to such restricted stock units, without interest and less any applicable withholding taxes;

· investment funds (the “CD&R Affiliates”) sponsored by, or affiliated with, CD&R invested $887.1 million in the common stock of Holding, the proceeds of which were contributed to Parent, and the remainder of the acquisition consideration for the Merger was funded through a variety of debt instruments;

· certain members of our management rolled over existing options to purchase Corporation common stock with an aggregate value of $28.3 million, based on the Merger consideration price, into options to purchase common stock of Holding; and

· Merger Sub merged with and into Corporation, with Corporation as the surviving corporation.

Financial Instruments and Concentration of Credit Risk

The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, other than current portion of self-insurance estimates, long-term debt and long-term liabilities, other than self-insurance estimates, constitute financial instruments. Based on management’s estimates, the carrying value of these financial instruments approximates their fair value as of September 30, 2013 and December 31, 2012. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2013, the Company derived approximately 28% of its revenue from Medicare and Medicaid, 68% from insurance providers and contracted payors, and 4% directly from patients.

The Company estimates the fair value of its fixed rate senior subordinated notes based on quoted market prices (Level 1). The estimated fair value of the senior subordinated notes at September 30, 2013 was approximately $1,029.1 million with a carrying value of $950.0 million. EMCA Insurance Company, Ltd. held $15 million of the senior subordinated notes at September 30, 2013.

Fair Value Measurement

The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include fixed income mortgage backed securities, corporate bonds, and derivatives.

Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2013 and December 31, 2012:

		September 30, 2013												December 31, 2012
Description		Level 1			Level 2			Level 3			Total			Level 1		Level 2		Level 3		Total
Assets:
Securities		$	18,053		$	517		$	—		$	18,570		$	22,870	$	788	$	—	$	23,658
Fuel hedge		$	—		$	538		$	—		$	538		$	—	$	631	$	—	$	631
Liabilities:
Contingent consideration		$	—		$	—		$	9,401		$	9,401		$	—	$	—	$	4,401	$	4,401
Interest rate swap		$	—		$	3,453		$	—		$	3,453		$	—	$	4,586	$	—	$	4,586

The contingent consideration balance classified as a Level 3 liability has increased by $5.0 million since December 31, 2012 due to recent acquisitions.

During the nine months ended September 30, 2013, we had no transfers in and out of Level 1 and Level 2 fair value measurements.

Recent Accounting Pronouncements

In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”) to provide explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. ASU 2013-11 requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except if such a deferred tax asset is unavailable at the reporting date. If a deferred tax asset is unavailable at the reporting date, then the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 31, 2013. We do not expect the adoption of ASU 2013-11 to have a material impact on our financial position or results of operations.

In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”) to improve the reporting of reclassifications out of accumulated other comprehensive income (“AOCI”).

ASU 2013-02 requires the following:

· present separately for each component of other comprehensive income, current period reclassifications out of AOCI and other amounts of current-period other comprehensive income; and

· separately provide information about the effects on net income of significant amounts reclassified out of each component of AOCI if those amounts all are required to be reclassified to net income in their entirety in the same reporting period.

The Company adopted this new guidance effective January 1, 2013 by adding disclosure in Note 8, Changes in Accumulated Other Comprehensive Income by Component.

Basic_and_Diluted_Net_Loss_Inc

Basic and Diluted Net (Loss) Income Per Share	9 Months Ended
	Sep. 30, 2013
Basic and Diluted Net (Loss) Income Per Share	'
Basic and Diluted Net (Loss) Income Per Share	'
	3. Basic and Diluted Net (Loss) Income Per Share

	Holding presents both basic (loss) earnings per share (“EPS”) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing “Net (loss) income” by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised. The potential dilution from stock awards was computed using the treasury stock method based on the average market value of Holding’s common stock. The following table presents EPS amounts for all periods and the basic and diluted weighted-average shares outstanding used in the calculation.

		Quarter ended					Nine months ended
		September 30,					September 30,
		2013			2012		2013			2012
	Net (loss) income	$	(7,663	)	$	15,209	$	(1,913	)	$	28,842

	Weighted-average common shares outstanding — common stock:
	Basic	157,282,885			130,230,634		139,969,940			130,219,651
	Dilutive impact of stock awards outstanding	—			3,233,248		—			2,260,170
	Diluted	157,282,885			133,463,882		139,969,940			132,479,821

	Earnings per share — common stock:
	Basic net (loss) income per common share	$	(0.05	)	$	0.12	$	(0.01	)	$	0.22
	Diluted net (loss) income per common share	$	(0.05	)	$	0.11	$	(0.01	)	$	0.22

	Holding had a net loss for the three and nine month periods ended September 30, 2013, therefore, the effect of stock awards to purchase common stock of 6,088,252 and 8,663,107, respectively, is excluded from the computations of diluted loss per share since the effect is anti-dilutive. As of September 30, 2012, there was no stock awards of common stock outstanding excluded from the weighted-average common shares outstanding above.

Acquisitions

Acquisitions	9 Months Ended
Acquisitions	Sep. 30, 2013
Acquisitions	'
Acquisitions	'
	4. Acquisitions

	During the quarter ended September 30, 2013, indirect, wholly-owned subsidiaries of the Company completed the acquisitions of CMORx, LLC, which provides clinical management software, each of T.M.S. Management Group, Inc. and Transportation Management Services of Brevard, Inc., two related corporations that manage the provision of non-emergency medical transportation services by third-party transportation service providers, and a clinical affiliate acquired certain assets of Jacksonville Emergency Consultants P.A., which provides facility based physician staffing in northern Florida, for a combined purchase price of $26.4 million. At September 30, 2013, the Company recorded $24.4 million to goodwill, $3.9 million to intangible assets, $1.6 million to property, plant, and equipment, and $3.5 million to net current liabilities, which are subject to adjustment based upon the completion of purchase price allocations.

	During the nine months ended September 30, 2013, the Company made purchase price allocation adjustments related to the acquisitions of Guardian Healthcare Group, Inc. (“Guardian”), the management services companies of NightRays, P.A (“NightRays”), and Saint Vincent Anesthesia Medical Group, Inc. / Golden State Anesthesia Consultants, Inc. These adjustments included reclassifications from goodwill to intangible assets of $8.7 million and $4.3 million for Guardian and NightRays, respectively, a deferred tax liability increase of $3.3 million and other adjustments to opening balances for assets and liabilities.

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities	'
Accrued Liabilities	'
	5. Accrued Liabilities

	Accrued liabilities were as follows at September 30, 2013 and December 31, 2012:

		September 30,			December 31,
		2013			2012
	Accrued wages and benefits	$	156,950		$	136,334
	Accrued paid time-off	27,267			25,626
	Current portion of self-insurance reserves	47,902			49,224
	Accrued restructuring	6,504			12,318
	Current portion of compliance and legal	6,166			3,711
	Accrued billing and collection fees	3,263			4,945
	Accrued incentive compensation	20,249			22,274
	Accrued interest	27,660			7,889
	Accrued income taxes	30,114			19,487
	Accrued dissenting shareholder settlement	—			41,826
	Other	56,643			63,796
	Total accrued liabilities — Corporation	$	382,718		$	387,430
	Adjustments for Holding:
	Accrued interest	—			10,406
	Accrued income taxes	(30,114		)	(8,901		)
	Total accrued liabilities — Holding	$	352,604		$	388,935

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2013
Long-Term Debt	'
Long-Term Debt	'
	6. Long-Term Debt

	Long-term debt and capital leases consisted of the following at September 30, 2013 and December 31, 2012:

		September 30,			December 31,
		2013			2012
	Senior subordinated unsecured notes due 2019	$	950,000		$	950,000
	Senior subordinated unsecured notes purchased by the Company’s subsidiary	(15,000		)	(15,000		)
	Senior secured term loan due 2018 (4.00% at September 30, 2013)	1,301,475			1,160,609
	ABL Facility	—			125,000
	Notes due at various dates from 2013 to 2022 with interest rates from 6% to 10%	861			1,149
	Capital lease obligations due at various dates from 2013 to 2018	387			447
		2,237,723			2,222,205
	Less current portion	(12,316		)	(12,282		)
	Total long-term debt — Corporation	$	2,225,407		$	2,209,923
	Senior PIK Toggle Notes due 2017	—			437,175
	Total long-term debt — Holding	$	2,225,407		$	2,647,098

	On February 7, 2013, Corporation entered into a First Amendment (the “Term Loan Amendment”) to the credit agreement dated as of May 25, 2011. Under the Term Loan Amendment, Corporation incurred an additional $150.0 million in incremental borrowings under the seven-year senior secured term loan facility (the, “Term Loan Facility”), the proceeds of which were used to pay down Corporation’s five-year senior secured asset-based loan facility (the “ABL Facility”), and, together with the Term Loan Facility, the “Credit Facilities”). In addition, the rate at which the loans under the Term Loan Credit Agreement bear interest was amended to equal (i) the higher of (x) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“LIBOR”) and (y) 1.00%, plus, in each case, 3.00% (with a step-down to 2.75% in the event that Corporation meets a consolidated first lien net leverage ratio of 2.50:1.00), or (ii) the alternate base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% and (z) 2.00%, plus, in each case, 2.00% (with a step-down to 1.75% in the event that Corporation meets a consolidated first lien net leverage ratio of 2.50:1.00). Corporation wrote off $0.1 million of unamortized debt issuance costs as a result of this modification.

	On February 27, 2013, Corporation entered into a First Amendment (the “ABL Amendment”) to the credit agreement governing the ABL Facility, under which Corporation increased its commitments under the ABL Facility to $450.0 million. In addition, the rate at which the loans under the ABL Credit Agreement bear interest was amended to equal (i) LIBOR plus, (x) 2.00% in the event that average daily excess availability is less than or equal to 33% of availability, (y) 1.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (z) 1.50% in the event that average daily excess availability is greater than 66% of availability, or (ii) the alternate base rate, which will be the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) 0.50% in excess of the overnight federal funds rate and (z) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% plus, in each case, (A) 1.00% in the event that average daily excess availability is less than or equal to 33% of availability, (B) 0.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (C) 0.50% in the event that average daily excess availability is greater than 66% of availability.

	Corporation recorded $5.0 million of debt issuance expense related to these amendments.

	On August 30, 2013, Holding redeemed all of the Senior PIK Toggle Notes due 2017 at a redemption price equal to 102.75% of the aggregate principal amount of the Senior PIK Toggle Notes due 2017, plus accrued and unpaid interest of $17.2 million. During the three and nine months ended September 30, 2013, Holding recorded $29.5 million in premiums and deferred financing costs related to the redemption of the Senior PIK Toggle Notes due 2017 as “Loss on early debt extinguishment” on Holding’s Consolidated Statements of Operations and Comprehensive (Loss) Income.

	During the second quarter of 2012, the Company’s captive insurance subsidiary purchased and currently holds $15.0 million of our 8.125% senior subordinated unsecured notes due 2019 through an open market transaction.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	9 Months Ended
Derivative Instruments and Hedging Activities	Sep. 30, 2013
Derivative Instruments and Hedging Activities	'
Derivative Instruments and Hedging Activities	'
	7. Derivative Instruments and Hedging Activities

	The Company manages its exposure to changes in fuel prices and interest rates and, from time to time, uses highly effective derivative instruments to manage well-defined risk exposures. The Company monitors its positions and the credit ratings of its counterparties and does not anticipate non-performance by the counterparties. The Company does not use derivative instruments for speculative purposes.

	At September 30, 2013, the Company was party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.65 to $4.02 per gallon. The Company purchases the diesel fuel at the market rate and periodically settles with its counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 3.4 million gallons, which represents approximately 27.2% of the Company’s total estimated usage during the periods hedged, and are spread over periods from October 2013 through December 2014. As of September 30, 2013, the Company recorded, as a component of other comprehensive income before applicable tax impacts, an asset associated with the fair value of the fuel hedge in the amount of $0.5 million, compared to an asset of $0.6 million as of December 31, 2012. Settlement of hedge agreements are included in operating expenses and resulted in net receipts from the counterparty of $0.1 million and $0.4 million for each of the three and nine month periods ended September 30, 2013, zero and $0.8 million for the three and nine months ended September 30, 2012. Over the next 12 months, the Company expects to reclassify $0.4 million of deferred gain from AOCI as the related fuel hedge transactions mature.

	In October 2011, the Company entered into interest rate swap agreements which mature on August 31, 2015. The swap agreements are with major financial institutions and effectively convert a total of $400 million in variable rate debt to fixed rate debt with an effective rate of 4.49%. The Company will continue to make interest payments based on the variable rate associated with the debt (based on LIBOR, but not less than 1.0%) and will periodically settle with its counterparties for the difference between the rate paid and the fixed rate. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability associated with the fair value of the interest rate swap in the amount of $3.5 million as of September 30, 2013, compared to $4.6 million as of December 31, 2012. Settlement of interest rate swap agreements are included in interest expense and resulted in net payments to the counterparties of $0.5 million and $1.5 million for each of the three and nine month periods ended September 30, 2013. There were no payments made or received under these hedge agreements as of September 30, 2012. Over the next 12 months, the Company expects to reclassify $2.0 million of deferred loss from AOCI to interest expense as the related interest rate swap transactions mature.

Changes_in_Accumulated_Other_C

Changes in Accumulated Other Comprehensive Income by Component	9 Months Ended
	Sep. 30, 2013
Changes in Accumulated Other Comprehensive Income by Component	'
Changes in Accumulated Other Comprehensive Income by Component	'
	8. Changes in Accumulated Other Comprehensive Income by Component

	The following table summarizes the changes in the Company’s AOCI by component for the nine months ended September 30, 2013. All amounts are after tax.

		Fuel hedge			Interest rate swap			Unrealized			Total
								holding gains on
								available-for-sale
								securities
	Balance as of December 31, 2012	$	1,057		$	(2,861	)	$	1,591		$	(213	)
	Other comprehensive income before reclassifications	(546		)	(222		)	(410		)	(1,178		)
	Amounts reclassified from accumulated other comprehensive income	(203		)	929			(172		)	554
	Net current-period other comprehensive income	(749		)	707			(582		)	(624		)
	Balance as of September 30, 2013	$	308		$	(2,154	)	$	1,009		$	(837	)

	The following table shows the line item on the Consolidated Statements of Operations affected by reclassifications out of AOCI.

		Amount reclassified from AOCI
		Quarter ended			Nine months ended			Affected line item on the
		September 30,			September 30,			Affected line item on the
	Details about AOCI components	2013			2013			Statement of Operations
	Gains and losses on cash flow hedges
	Fuel hedge	$	106		$	326		Operating expenses
	Interest rate swap	(502		)	(1,489		)	Interest expense
		(396		)	(1,163		)	Total before tax
		149			437			Tax benefit
		$	(247	)	$	(726	)	Net of tax

	Unrealized holding gains on available-for-sale securities	$	158		$	276		Realized gain on investments
		158			276			Total before tax
		(59		)	(104		)	Tax expense
		$	99		$	172		Net of tax

Restructuring_Charges

Restructuring Charges	9 Months Ended
	Sep. 30, 2013
Restructuring Charges	'
Restructuring Charges	'
	9. Restructuring Charges

	The Company recorded a restructuring charge of $1.3 million and $5.0 million during the three and nine months ended September 30, 2013, respectively, and $2.0 million and $10.8 million during the three and nine months ended September 30, 2012, respectively related to continuing efforts to re-align AMR’s operations and the reorganization of EmCare’s geographic regions. Payments currently under this plan are expected to be complete by March 2015. The accrued restructuring liability at September 30, 2013 of $6.5 million includes lease abandonment accruals on restructuring plans from prior years in addition to the 2012 plan outlined below.

		2012 Plan
		Lease & Other			Severance			Total
		Contract
		Termination Costs
	Balance as of December 31, 2012	$	6,295		$	4,058		$	10,353
	Incurred	1,885			3,107			4,992
	Paid	(5,902		)	(4,064		)	(9,966		)
	Balance as of September 30, 2013	$	2,278		$	3,101		$	5,379

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	10. Commitments and Contingencies

	Lease Commitments

	The Company leases various facilities and equipment under operating lease agreements.

	The Company also leases certain assets under capital leases. Assets under capital leases are capitalized using inherent interest rates at the inception of each lease. Capital leases are collateralized by the underlying assets.

	Services

	The Company is subject to the Medicare and Medicaid fraud and abuse laws which prohibit, among other things, any false claims, or any bribe, kickback or rebate in return for the referral of Medicare and Medicaid patients. Violation of these prohibitions may result in civil and criminal penalties and exclusion from participation in the Medicare and Medicaid programs. Management has implemented policies and procedures that management believes will assure that the Company is in substantial compliance with these laws and regulations but there can be no assurance the Company will not be found to have violated certain of these laws and regulations. From time to time, the Company receives requests for information from government agencies pursuant to their regulatory or investigational authority. Such requests can include subpoenas or demand letters for documents to assist the government agencies in audits or investigations. The Company is cooperating with the government agencies conducting these investigations and is providing requested information to the government agencies. Other than the proceedings described below, management believes that the outcome of any of these investigations would not have a material adverse effect on the Company.

	Like other ambulance companies, AMR has provided discounts to its healthcare facility customers (nursing homes and hospitals) in certain circumstances. The Company has attempted to comply with applicable law where such discounts are provided. During the first quarter of fiscal 2004, the Company was advised by the U.S. Department of Justice (“DOJ”) that it was investigating certain business practices at AMR. The specific practices at issue were (1) whether ambulance transports involving Medicare eligible patients complied with the “medical necessity” requirement imposed by Medicare regulations, (2) whether patient signatures, when required, were properly obtained from Medicare eligible patients, and (3) whether discounts in violation of the federal Anti-Kickback Statute were provided by AMR in exchange for referrals involving Medicare eligible patients. In connection with the third issue, the government alleged that certain of AMR’s hospital and nursing home contracts in effect in Texas in periods prior to 2002 contained discounts in violation of the federal Anti-Kickback Statute. The Company negotiated a settlement with the government pursuant to which the Company paid $9 million and obtained a release of all claims related to such conduct alleged to have occurred in Texas in periods prior to 2002. In connection with the settlement, AMR entered into a Corporate Integrity Agreement (“CIA”) which was effective for a period of five years beginning September 12, 2006, and which was released in February 2012.

	In December 2006, AMR received a subpoena from the DOJ. The subpoena requested copies of documents for the period from January 2000 through the present. The subpoena required AMR to produce a broad range of documents relating to the operations of certain AMR affiliates in New York. The Company produced documents responsive to the subpoena. The government identified claims for reimbursement that the government believes lack support for the level billed, and invited the Company to respond to the identified areas of concern. The Company reviewed the information provided by the government and provided its response. On May 20, 2011, AMR entered into a settlement agreement with the DOJ and a CIA with the Office of Inspector General of the Department of Health and Human Services (“OIG”) in connection with this matter. Under the terms of the settlement, AMR paid $2.7 million to the federal government. In connection with the settlement, the Company entered into a CIA with a five- year period beginning May 20, 2011. Pursuant to this CIA, the Company is required to maintain a compliance program, which includes, among other elements, the appointment of a compliance officer and committee, training of employees nationwide, safeguards for its billing operations as they relate to services provided in New York, including specific training for operations and billing personnel providing services in New York, review by an independent review organization and reporting of certain reportable events. The Company entered into the settlement in order to avoid the uncertainties of litigation, and has not admitted any wrongdoing. In May 2013, a subsidiary of the Company entered into an agreement to divest substantially all the assets underlying AMR’s services in New York, although the obligations of the Company’s compliance program will remain in effect following the expected divestiture. The divesture was completed on July 1, 2013.

	In July 2011, AMR received a subpoena from the Civil Division of the U.S. Attorney’s Office for the Central District of California (“USAO”) seeking certain documents concerning AMR’s provision of ambulance services within the City of Riverside, California. The USAO indicated that it, together with the OIG, was investigating whether AMR violated the federal False Claims Act and/or the federal Anti-Kickback Statute in connection with AMR’s provision of ambulance transport services within the City of Riverside. The California Attorney General’s Office conducted a parallel state investigation for possible violations of the California False Claims Act. In December 2012, AMR was notified that both investigations were concluded and that the agencies had closed the matter. There were no findings made against AMR, and the closure of the matter did not require any payments from AMR.

	Other Legal Matters

	Four different lawsuits purporting to be class actions have been filed against AMR and certain subsidiaries in California alleging violations of California wage and hour laws. On April 16, 2008, Lori Bartoni commenced a suit in the Superior Court for the State of California, County of Alameda; on July 8, 2008, Vaughn Banta filed suit in the Superior Court of the State of California, County of Los Angeles; on January 22, 2009, Laura Karapetian filed suit in the Superior Court of the State of California, County of Los Angeles; and on March 11, 2010, Melanie Aguilar filed suit in Superior Court of the State of California, County of Los Angeles. The Banta, Aguilar and Karapetian cases have been coordinated in the Superior Court for the State of California, County of Los Angeles. At the present time, courts have not certified classes in any of these cases. Plaintiffs allege principally that the AMR entities failed to pay overtime charges pursuant to California law, and failed to provide required meal breaks, rest breaks or pay premium compensation for missed breaks. Plaintiffs are seeking to certify the classes and are seeking lost wages, punitive damages, attorneys’ fees and other sanctions permitted under California law for violations of wage hour laws. We are unable at this time to estimate the amount of potential damages, if any.

	Merion Capital, L.P. (“Merion”), a former stockholder of Corporation, filed an action in the Delaware Court of Chancery seeking to exercise its right to appraisal of its holdings in Corporation prior to the Merger. During the nine months ended September 30, 2013, the Company expensed $8.4 million of legal settlement costs and $1.9 million of interest. On April 15, 2013, the Company paid $52.1 million in a settlement of Merion’s appraisal action, in which Merion agreed to release its claims against the Company. $13.7 million of this payment is included in cash flows from operations and $38.3 million is included in cash flows from financing activities on the statements of cash flows for the nine months ended September 30, 2013.

	On August 7, 2012, EmCare received a subpoena from the OIG. The subpoena requests copies of documents for the period from January 1, 2007 through the present and appears to primarily be focused on EmCare’s contracts for services at hospitals that are affiliated with Health Management Associates, Inc. The Company intends to cooperate with the government during its investigation and, as such, is in the process of gathering responsive documents, formulating a written response to the subpoena and is seeking to engage in a meaningful dialogue with the relevant government representatives. At this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

	On February 5, 2013, AMR’s Air Ambulance Specialists, Inc. subsidiary received a subpoena from the Federal Aviation Administration relating to its operations as an indirect air carrier and its relationships with Part 135 direct air carriers. The Company intends to cooperate with the government during its investigation and, as such, is in the process of gathering responsive documents, formulating a written response to the subpoena and is seeking to engage in a meaningful dialogue with the relevant government representatives. At this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

	On February 14, 2013, EmCare received a subpoena from the OIG requesting documents and other information relating to EmCare’s relationship with Community Health Services, Inc. (“CHS”). The Company intends to cooperate with the government during its investigation. At this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

	The Company is involved in other litigation arising in the ordinary course of business. Management believes the outcome of these legal proceedings will not have a material adverse impact on its financial condition, results of operations or liquidity.

Equity_Based_Compensation

Equity Based Compensation	9 Months Ended
Equity Based Compensation	Sep. 30, 2013
Equity Based Compensation	'
Equity Based Compensation	'
	11. Equity Based Compensation

	Holding established a stock compensation plan (“Stock Compensation Plan”) after the Merger whereby certain members of management, officers and directors were awarded stock options in Holding. These options have a $3.69 strike price, which was reduced from the original strike price of $6.88 in connection with a dividend paid by Holding in October 2012. They vest ratably through December 2015 and have a maximum term of 10 years. A compensation charge of $1.1 million and $3.2 million was recorded for the three and nine months ended September 30, 2013, respectively, compared to compensation charges of $1.1 million and $3.2 million for the three and nine months ended September 30, 2012, respectively.

	Our external directors elected to receive part of their director fees in the form of restricted stock units (“RSUs”). As of September 30, 2013, the Company had granted 36,679 RSUs based on a market price of $6.88 per share, 7,328 RSUs based on a market price of $8.60 per share, 25,052 RSUs based on a market price of $5.41 per share, 9,214 RSUs based on a market price of $7.85 per share, and 641 RSUs based on a market price of $23.00 per share as annual director fees. The RSUs are fully vested when granted.

	Upon completion of Holding’s initial public offering, the Stock Compensation Plan terminated and a new stock compensation plan was adopted (“Omnibus Incentive Plan”), pursuant to which the Company will make grants of incentive compensation to its directors, officers and other employees. Under the terms of the Omnibus Incentive Plan, each non-employee director will receive a cash award in addition to an annual award of RSUs with a fair market value equal to $100,000 on the date of grant. There were no grants awarded to non-employee directors under the Omnibus Incentive Plan as of September 30, 2013.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2013
Related Party Transactions	'
Related Party Transactions	'
	12. Related Party Transactions

	Holding and Corporation were party to the Consulting Agreement with CD&R, pursuant to which CD&R provided the Company and its subsidiaries with financial, investment banking, management, advisory and other services in exchange for an annual fee of $5.0 million. The Company expensed $20.6 million and $23.1 million for the three and nine months ended September 30, 2013, respectively, and $1.3 million and $3.8 million for the three and nine months ended September 30, 2012, respectively, in respect of this fee. During the quarter ended September 30, 2013, the Company made a $20.0 million payment to CD&R with proceeds received from the initial public offering of Common Stock of Holding to terminate the Consulting Agreement.

	On April 1, 2013, Corporation declared and paid a dividend to Parent which in turn paid a dividend to Holding in the amount of $20.8 million. These funds were used by Holding to pay interest due on Holding’s Senior PIK Toggle Notes due 2017.

	During the quarter ended September 30, 2013, Holding made an $86.1 million distribution to Corporation with proceeds received from the initial public offering of Common Stock of Holding to pay off debt and for other general corporate purposes.

Variable_Interest_Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2013
Variable Interest Entities	'
Variable Interest Entities	'
	13. Variable Interest Entities

	GAAP requires the assets, liabilities, noncontrolling interests and activities of Variable Interest Entities (“VIEs”) to be consolidated if an entity’s interest in the VIE has specific characteristics including: voting rights not proportional to ownership and the right to receive a majority of expected income or absorb a majority of expected losses. In addition, the entity exposed to the majority of the risks and rewards associated with the VIE is deemed its primary beneficiary and must consolidate the entity.

	EmCare entered into an agreement in 2011 with an indirect wholly-owned subsidiary of HCA Holdings Inc. to form an entity which would provide physician services to various healthcare facilities (“HCA-EmCare JV”). HCA-EmCare JV began providing services to healthcare facilities during the first quarter of 2012 and meets the definition of a VIE. The Company determined that, although EmCare only holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

	· EmCare provides management services to HCA-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of HCA-EmCare JV’s activities involve EmCare; and

	· as payment for management services, EmCare is entitled to receive a base management fee from HCA-EmCare JV as well as a bonus management fee.

	The following is a summary of the HCA-EmCare JV assets and liabilities as of September 30, 2013 and December 31, 2012, which are included in the Company’s consolidated financial statements.

		September 30,		December 31,
		2013		2012
	Current assets	$	67,238,293	$	33,141,502
	Current liabilities	46,290,990		20,081,084

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2013
Segment Information	'
Segment Information	'
	14. Segment Information

	The Company is organized around two separately managed business units: outsourced facility-based physician services and medical transportation services, which have been identified as operating segments. The facility-based physician services reportable segment provides physician services to hospitals primarily for emergency departments (“ED”) and urgent care centers, as well as for hospitalist/inpatient, radiology, tele-radiology, anesthesiology and surgery services. The medical transportation services reportable segment focuses on providing a full range of medical transportation services from basic patient transit to the most advanced emergency care and pre-hospital assistance. The Chief Executive Officer has been identified as the chief operating decision maker (“CODM”) as he assesses the performance of the business units and decides how to allocate resources to the business units.

	Net (loss) income before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), interest and other income (expense), loss on early debt extinguishment, realized gain (loss) on investments, interest expense, equity-based compensation, related party management fees, restructuring charges, and depreciation and amortization expense (“Adjusted EBITDA”) is the measure of profit and loss that the CODM uses to assess performance, measure liquidity and make decisions. The Company modified the definition of Adjusted EBITDA following the Merger. The accounting policies for reported segments are the same as for the Company as a whole.

	The following tables present the Company’s operating segment results for the three and nine months ended September 30, 2013 and 2012:

			Quarter ended						Nine months ended
			September 30,						September 30,
			2013			2012			2013			2012
	Facility-Based Physician Services
	Net revenue		$	605,105		$	485,936		$	1,729,158		$	1,403,792
	Segment Adjusted EBITDA		82,032			68,750			218,767			189,231
	Medical Transportation Services
	Net revenue		350,783			334,875			1,014,309			1,024,411
	Segment Adjusted EBITDA		39,623			34,690			109,843			102,105
	Total
	Total net revenue		955,888			820,811			2,743,467			2,428,203
	Total Segment Adjusted EBITDA — Corporation		121,655			103,440			328,610			291,336
	Other operating income (expenses) — Holding		15			—			(73		)	—
	Total Segment Adjusted EBITDA — Holding		121,670			103,440			328,537			291,336
	Reconciliation of Adjusted EBITDA to Net Income
	Segment Adjusted EBITDA — Corporation		$	121,655		$	103,440		$	328,610		$	291,336
	Depreciation and amortization expense		(35,175		)	(30,592		)	(104,552		)	(91,844		)
	Restructuring charges		(1,319		)	(2,028		)	(4,988		)	(10,751		)
	Equity-based compensation expense		(1,062		)	(1,062		)	(3,186		)	(3,186		)
	Related party management fees		(20,609		)	(1,250		)	(23,109		)	(3,750		)
	Interest expense		(39,131		)	(41,322		)	(117,959		)	(126,288		)
	Realized gain on investments		158			5			276			366
	Interest and other (expense) income		(52		)	937			(13,022		)	1,340
	Loss on early debt extinguishment		—			(1,561		)	(122		)	(6,733		)
	Income tax expense		(9,816		)	(11,448		)	(27,782		)	(21,952		)
	Equity in earnings of unconsolidated subsidiary		68			90			230			304
	Net income — Corporation		$	14,717		$	15,209		$	34,396		$	28,842
	Adjustments for Holding:
	Other operating income (expenses)		15			—			(73		)	—
	Loss on early debt extinguishment		(29,519		)	—			(29,519		)	—
	Interest expense		(7,641		)	—			(30,567		)	—
	Income tax benefit		14,765			—			23,850			—
	Net (loss) income — Holding		$	(7,663	)	$	15,209		$	(1,913	)	$	28,842

	A reconciliation of Segment Adjusted EBITDA to cash flows provided by operating activities is as follows:

			Quarter ended						Nine months ended
			September 30,						September 30,
			2013			2012			2013			2012
	Segment Adjusted EBITDA — Corporation		$	121,655		$	103,440		$	328,610		$	291,336
	Related party management fees		(20,609		)	(1,250		)	(23,109		)	(3,750		)
	Restructuring charges		(1,319		)	(2,028		)	(4,988		)	(10,751		)
	Interest expense (less deferred loan fee amortization)		(35,303		)	(37,328		)	(106,644		)	(113,923		)
	Payment of dissenting shareholder settlement		—			—			(13,717		)	—
	Change in accounts receivable		(69,716		)	(25,547		)	(126,237		)	(68,376		)
	Change in other operating assets/liabilities		65,738			36,606			51,038			51,474
	Excess tax benefits from equity-based compensation		—			—			(3,168		)	—
	Interest and other income (expense)		(52		)	937			(13,022		)	1,340
	Income tax benefit (expense), net of change in deferred taxes		(9,729		)	31,491			(25,538		)	21,194
	Other		89			(205		)	775			703
	Cash flows provided by operating activities - Corporation		$	50,754		$	106,116		$	64,000		$	169,247
	Adjustments for Holding:
	Other operating income (expenses)		15			—			(73		)	—
	Interest expense (less deferred loan fee amortization)		(6,936		)	—			(27,749		)	—
	Change in accounts receivable		(1,827		)	—			(269		)	—
Change in other operating assets/liabilities		(25,050		)	—			(36,209		)	—
Income tax benefit, net of change in deferred taxes		14,766			—			25,925			—
Cash flows provided by operating activities — Holding		$	31,722		$	106,116		$	25,625		$	169,247

Guarantors_of_Debt

Guarantors of Debt	9 Months Ended
	Sep. 30, 2013
Guarantors of Debt	'
Guarantors of Debt	'
	15. Guarantors of Debt

	Corporation is the issuer of the senior unsecured notes and the borrower under the Credit Facilities. The senior unsecured notes and the Credit Facilities are guaranteed by each of Corporation’s domestic subsidiaries, except for any subsidiaries subject to regulation as an insurance company, including Corporation’s captive insurance subsidiary. All of the operating income and cash flow of Corporation is generated by EmCare, AMR and their subsidiaries. As a result, funds necessary to meet the debt service obligations under the senior unsecured notes and the Credit Facilities are provided by the distributions or advances from the subsidiary companies, EmCare and AMR. Investments in subsidiary operating companies are accounted for on the equity method. Accordingly, entries necessary to consolidate Corporation and all of its subsidiaries are reflected in the Eliminations/Adjustments column. Separate complete financial statements of Corporation and subsidiary guarantors would not provide additional material information that would be useful in assessing the financial composition of Corporation or the subsidiary guarantors.

	Corporation’s payment obligations under the senior unsecured notes are jointly and severally guaranteed on a senior unsecured basis by the guarantors. Each of the guarantors is wholly owned, directly or indirectly, by Corporation, and all guarantees are full and unconditional. A guarantor will be released from its obligations under its guarantee under certain customary circumstances, including (i) the sale or disposition of the guarantor, (ii) the release of the guarantor from all of its obligations under all guarantees related to any indebtedness of Corporation, (iii) the merger or consolidation of the guarantor as specified in the indenture governing the senior unsecured notes, (iv) the guarantor becomes an unrestricted subsidiary, (v) the defeasance of Corporation’s obligations under the indenture governing the senior unsecured notes or (vi) the payment in full of the principal amount of the senior unsecured notes.

	The condensed consolidating financial statements for Corporation, the guarantors and the non-guarantors are as follows:

	Consolidating Statements of Operations

			For the three months ended September 30, 2013
						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Net revenue		$	—		$	955,403		$	19,415		$	(18,930	)	$	955,888
	Compensation and benefits		—			677,618			179			—			677,797
	Operating expenses		—			110,396			8			—			110,404
	Insurance expense		—			30,841			15,063			(18,930		)	26,974
	Selling, general and administrative expenses		—			40,714			17			—			40,731
	Depreciation and amortization expense		—			35,171			4			—			35,175
	Restructuring charges		—			1,319			—			—			1,319
	Income from operations		—			59,344			4,144			—			63,488
	Interest (loss) income from restricted assets		—			2			—			—			2
	Interest expense		—			(39,131		)	—			—			(39,131		)
	Realized (loss) gain on investments		—			158			—			—			158
	Interest and other expense		—			(6		)	(46		)	—			(52		)
	Income before taxes and equity in earnings of unconsolidated subsidiary		—			20,367			4,098			—			24,465
	Income tax expense		—			(9,811		)	(5		)	—			(9,816		)
	Income before equity in earnings of unconsolidated subsidiary		—			10,556			4,093			—			14,649
	Equity in earnings of unconsolidated subsidiary		14,717			—			68			(14,717		)	68
	Net income (loss)		$	14,717		$	10,556		$	4,161		$	(14,717	)	$	14,717

			For the three months ended September 30, 2012
						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Net revenue		$	—		$	820,352		$	18,708		$	(18,249	)	$	820,811
	Compensation and benefits		—			577,347			155			—			577,502
	Operating expenses		—			100,609			8			—			100,617
	Insurance expense		—			21,187			19,969			(18,249		)	22,907
	Selling, general and administrative expenses		—			18,534			7			—			18,541
	Depreciation and amortization expense		—			30,592			—			—			30,592
	Restructuring charges		—			2,028			—			—			2,028
	Income from operations		—			70,055			(1,431		)	—			68,624
	Interest income from restricted assets		—			(1,817		)	1,701			—			(116		)
	Interest expense		—			(41,322		)	—			—			(41,322		)
	Realized gain on investments		—			(1		)	6			—			5
	Interest and other income		—			973			(36		)	—			937
	Loss on early debt extinguishment		—			(1,561		)	—			—			(1,561		)
	Income before taxes and equity in earnings of unconsolidated subsidiary		—			26,327			240			—			26,567
	Income tax expense		—			(11,443		)	(5		)	—			(11,448		)
	Income before equity in earnings of unconsolidated subsidiary		—			14,884			235			—			15,119
	Equity in earnings of unconsolidated subsidiary		15,209			—			90			(15,209		)	90
	Net income (loss)		$	15,209		$	14,884		$	325		$	(15,209	)	$	15,209

			For the nine months ended September 30, 2013
						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Net revenue		$	—		$	2,742,003		$	57,024		$	(55,560	)	$	2,743,467
	Compensation and benefits		—			1,963,022			524			—			1,963,546
	Operating expenses		—			313,055			20			—			313,075
	Insurance expense		—			78,623			55,584			(55,560		)	78,647
	Selling, general and administrative expenses		—			86,476			42			—			86,518
	Depreciation and amortization expense		—			104,538			14			—			104,552
	Restructuring charges		—			4,988			—			—			4,988
Income from operations		—			191,301			840			—			192,141
Interest (loss) income from restricted assets		—			(3,002		)	3,636			—			634
Interest expense		—			(117,959		)	—			—			(117,959		)
Realized (loss) gain on investments		—			37			239			—			276
Interest and other expense		—			(12,913		)	(109		)	—			(13,022		)
Loss on early debt extinguishment		—			(122		)	—			—			(122		)
Income before taxes and equity in earnings of unconsolidated subsidiary		—			57,342			4,606			—			61,948
Income tax expense		—			(27,765		)	(17		)	—			(27,782		)
Income before equity in earnings of unconsolidated subsidiary		—			29,577			4,589			—			34,166
Equity in earnings of unconsolidated subsidiary		34,396			—			230			(34,396		)	230
Net income (loss)		$	34,396		$	29,577		$	4,819		$	(34,396	)	$	34,396

		For the nine months ended September 30, 2012
					Subsidiary			Subsidiary			Eliminations/
		Corporation			Guarantors			Non-Guarantor			Adjustments			Total
Net revenue		$	—		$	2,426,835		$	56,650		$	(55,282	)	$	2,428,203
Compensation and benefits		—			1,705,758			447			—			1,706,205
Operating expenses		—			304,991			14			—			305,005
Insurance expense		—			70,435			60,199			(55,282		)	75,352
Selling, general and administrative expenses		—			57,655			15			—			57,670
Depreciation and amortization expense		—			91,844			—			—			91,844
Restructuring charges		—			10,751			—			—			10,751
Income from operations		—			185,401			(4,025		)	—			181,376
Interest income from restricted assets		—			(2,908		)	3,337			—			429
Interest expense		—			(126,288		)	—			—			(126,288		)
Realized gain on investments		—			(1,176		)	1,542			—			366
Interest and other income (expense)		—			1,463			(123		)	—			1,340
Loss on early debt extinguishment		—			(6,733		)	—			—			(6,733		)
Income before taxes and equity in earnings of unconsolidated subsidiary		—			49,759			731			—			50,490
Income tax expense		—			(21,937		)	(15		)	—			(21,952		)
Income before equity in earnings of unconsolidated subsidiary		—			27,822			716			—			28,538
Equity in earnings of unconsolidated subsidiary		28,842			—			304			(28,842		)	304
Net income (loss)		$	28,842		$	27,822		$	1,020		$	(28,842	)	$	28,842

Consolidating Balance Sheet
As of September 30, 2013

					Subsidiary			Subsidiary			Eliminations/
		Corporation			Guarantors			Non-Guarantor			Adjustments			Total
Assets
Current assets:
Cash and cash equivalents		$	—		$	52,624		$	56,415		$	(15,000	)	$	94,039
Insurance collateral		—			9,431			73,500			(53,892		)	29,039
Trade and other accounts receivable, net		—			748,544			3,614			(1,674		)	750,484
Parts and supplies inventory		—			22,526			13			—			22,539
Prepaids and other current assets		4,323			23,628			452			—			28,403
Current deferred tax assets		—			—			3,515			(3,515		)	—
Current assets		4,323			856,753			137,509			(74,081		)	924,504
Non-current assets:
Property, plant, and equipment, net		—			190,837			—			—			190,837
Intercompany receivable		2,253,808			—			10,383			(2,264,191		)	—
Intangible assets, net		—			524,317			—			—			524,317
Non-current deferred tax assets		—			—			3,125			(3,125		)	—
Insurance collateral		—			72,015			12,107			(72,015		)	12,107
Goodwill		—			2,440,476			125			(2,981		)	2,437,620
Other long-term assets		66,753			—			1,252			7,964			75,969
Investment and advances in subsidiaries		1,033,139			4,379			6,998			(1,044,516		)	—
Assets		$	3,358,023		$	4,088,777		$	171,499		$	(3,452,945	)	$	4,165,354
Liabilities and Equity
Current liabilities:
Accounts payable		$	—		$	65,107		$	134		$	—		$	65,241
Accrued liabilities		30,657			340,355			15,093			(3,387		)	382,718
Current deferred tax liabilities		—			31,741			—			(3,515		)	28,226
Current portion of long-term debt		11,872			444			—			—			12,316
Current liabilities		42,529			437,647			15,227			(6,902		)	488,501
Long-term debt		2,239,604			803			—			(15,000		)	2,225,407
Long-term deferred tax liabilities		—			161,970			—			(5,120		)	156,850
Insurance reserves and other long-term liabilities		—			184,497			151,893			(124,214		)	212,176
Intercompany payable		—			2,264,191			—			(2,264,191		)	—
Liabilities		2,282,133			3,049,108			167,120			(2,415,427		)	3,082,934
Equity:
Common stock		—			—			30			(30		)	—
Treasury stock		(1,347		)	—			—			—			(1,347		)
Additional paid-in capital		1,003,013			963,264			—			(963,264		)	1,003,013
Retained earnings		75,061			71,925			3,136			(75,061		)	75,061
Accumulated other comprehensive loss		(837		)	(2,050		)	1,213			837			(837		)
Total Corporation equity		1,075,890			1,033,139			4,379			(1,037,518		)	1,075,890
Noncontrolling interest		—			6,530			—			—			6,530
Total equity		1,075,890			1,039,669			1,243			(1,037,518		)	1,082,420
Liabilities and Equity		$	3,358,023		$	4,088,777		$	171,499		$	(3,452,945	)	$	4,165,354

Consolidating Balance Sheet
As of December 31, 2012

		Corporation			Subsidiary			Subsidiary			Eliminations/			Total
					Guarantors			Non-			Adjustments
								Guarantor
Assets
Current assets:
Cash and cash equivalents		$	—		$	6,924		$	65,627		$	(15,000	)	$	57,551
Insurance collateral		—			6,626			35,975			(18,120		)	24,481
Trade and other accounts receivable, net		—			623,651			3,738			(1,976		)	625,413
Parts and supplies inventory		—			22,041			9			—			22,050
Prepaids and other current assets		—			23,679			297			(462		)	23,514
Current deferred tax assets		—			—			3,447			(3,447		)	—
Current assets		—			682,921			109,093			(39,005		)	753,009
Non-current assets:
Property, plant, and equipment, net		—			191,864			—			—			191,864
Intercompany receivable		2,237,508			—			11,596			(2,249,104		)	—
Intangible assets, net		—			564,218			—			—			564,218
Non-current deferred tax assets		—			—			1,097			(1,097		)	—
Insurance collateral		—			65,762			5,491			(50,493		)	20,760
Goodwill		—			2,416,613			—			(2,981		)	2,413,632
Other long-term assets		84,538			—			1,580			(261		)	85,857
Investment and advances in subsidiaries		930,119			3,001			—			(933,120		)	—
Assets		$	3,252,165		$	3,924,379		$	128,857		$	(3,276,061	)	$	4,029,340
Liabilities and Equity
Current liabilities:
Accounts payable		$	—		$	53,505		$	287		—			$	53,792
Accrued liabilities		47,184			328,153			15,782			(3,689		)	387,430
Current deferred tax liabilities		—			27,015			—			(3,447		)	23,568
Current portion of long-term debt		11,871			411			—			—			12,282
Current liabilities		59,055			409,084			16,069			(7,136		)	477,072
Long-term debt		2,223,738			1,185			—			(15,000		)	2,209,923
Long-term deferred tax liabilities		—			159,942			—			(3,092		)	156,850
Insurance reserves and other long-term liabilities		—			168,415			109,787			(68,609		)	209,593
Intercompany payable		—			2,249,104			—			(2,249,104		)	—
Liabilities		2,282,793			2,987,730			125,856			(2,342,941		)	3,053,438
Equity:
Common stock		—			—			30			(30		)	—
Treasury stock		(381		)	—			—			—			(381		)
Additional paid-in capital		908,488			871,306			—			(871,306		)	908,488
Retained earnings		61,478			59,206			2,272			(61,478		)	61,478
Accumulated other comprehensive loss		(213		)	(393		)	699			(306		)	(213		)
Total Corporation equity		969,372			930,119			3,001			(933,120		)	969,372
Noncontrolling interest		—			6,530			—			—			6,530
Total equity		969,372			936,649			3,001			(933,120		)	975,902
Liabilities and Equity		$	3,252,165		$	3,924,379		$	128,857		$	(3,276,061	)	$	4,029,340

Condensed Consolidating Statement of Cash Flows

		For the nine months ended September 30, 2013
					Subsidiary			Subsidiary
		Corporation			Guarantors			Non-guarantors			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		$	—		$	91,441		$	(34,489	)	$	56,952
Cash Flows from Investing Activities
Purchase of property, plant and equipment		—			(45,493		)	—			(45,493		)
Proceeds from sale of property, plant and equipment		—			396			—			396
Acquisition of businesses, net of cash received		—			(27,358		)	—			(27,358		)
Net change in insurance collateral		—			(24,102		)	26,982			2,880
Other investing activities		—			(456		)	—			(456		)
Net cash (used in) provided by investing activities		—			(97,013		)	26,982			(70,031		)
Cash Flows from Financing Activities
Corporation issuance of class A common stock		1,117			—			—			1,117
Borrowings under senior secured term loan facility		150,000			—			—			150,000
Capital contributed by Holding		85,073			—			—			85,073
Repayments of senior secured term loan facility and other debt		(10,383		)	—			—			(10,383		)
Net payments under ABL credit facility		—			(125,000		)	—			(125,000		)
Debt issue costs		(5,007		)	—			—			(5,007		)
Excess tax benefits from stock-based compensation		—			3,168			—			3,168
Dividend paid		—			(20,813		)	—			(20,813		)
Payment of dissenting shareholder settlement		—			(38,336		)	—			(38,336		)
Net change in bank overdrafts		—			1,686			—			1,686
Net intercompany borrowings (payments)		(220,800		)	222,505			(1,705		)	—
Net cash (used in) provided by financing activities		—			43,210			(1,705		)	41,505
Change in cash and cash equivalents		—			37,638			(9,212		)	28,426
Cash and cash equivalents, beginning of period		—			6,925			50,626			57,551
Cash and cash equivalents, end of period		$	—		$	44,563		$	41,414		$	85,977

		For the nine months ended September 30, 2012
					Subsidiary			Subsidiary
		Corporation			Guarantors			Non-guarantors			Total
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		$	—		$	223,882		$	(54,635	)	$	169,247
Cash Flows from Investing Activities
Purchase of property, plant and equipment		—			(44,311		)	—			(44,311		)
Proceeds from sale of property, plant and equipment		—			7,092			—			7,092
Acquisition of businesses, net of cash received		—			(20,559		)	—			(20,559		)
Net change in insurance collateral		—			(33,717		)	124,318			90,601
Other investing activities		—			589			—			589
Net cash (used in) provided by investing activities		—			(90,906		)	124,318			33,412
Cash Flows from Financing Activities
Repayments of debt and capital lease obligations		(225,616		)	—			—			(225,616		)
Debt issue costs		(95		)	—			—			(95		)
Repayment of equity		(528		)	—			—			(528		)
Proceeds from noncontrolling interest		—			6,530			—			6,530
Net change in bank overdrafts		—			11,455			—			11,455
Net intercompany borrowings (payments)		226,239			(199,043		)	(27,196		)	—
Net cash used in financing activities		—			(181,058		)	(27,196		)	(208,254		)
Change in cash and cash equivalents		—			(48,082		)	42,487			(5,595		)
Cash and cash equivalents, beginning of period		—			104,657			29,366			134,023
Cash and cash equivalents, end of period		$	—		$	56,575		$	71,853		$	128,428

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2013
Equity Structure	'
Consolidation	'
	Consolidation

	The consolidated financial statements of Holding include all of its wholly-owned subsidiaries, including Corporation and its respective subsidiaries and affiliated physician groups. The consolidated financial statements of Corporation, include all of its wholly-owned subsidiaries, including EmCare and AMR and their respective subsidiaries, and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates	'
	Use of Estimates

	The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.

Insurance	'
	Insurance

	Insurance collateral is comprised principally of government and investment grade securities and cash deposits with third parties and supports the Company’s insurance program and reserves. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. Insurance collateral also includes a receivable from insurers of $1.3 million and $1.6 million as of September 30, 2013 and December 31, 2012, respectively, for liabilities in excess of our self-insured retention.

	Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first $1 to $3 million of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

	The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims, other than general liability claims, are discounted at a rate of 1.5%. General liability claims are not discounted.

	The Company’s most recent actuarial valuation was completed in September 2013. As a result of this and previous actuarial valuations, the Company recorded increases in its provisions for insurance liabilities of $1.6 million and $1.2 million during the three and nine month periods ended September 30, 2013, respectively, compared to increases of $0.9 million and $0.3 million for three and nine month periods ended September 30, 2012, respectively, related to reserves for losses in prior years.

	The long-term portion of insurance reserves was $192.8 million and $189.4 million as of September 30, 2013 and December 31, 2012, respectively.
Trade and Other Accounts Receivable, net	'
	Trade and Other Accounts Receivable, net

	The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee for service charges as of December 31, 2012 was equal to approximately 97% and 93% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances are as follows:

		September 30,			December 31,
		2013			2012
	Gross trade accounts receivable	$	3,570,888		$	3,085,758
	Allowance for contractual discounts	1,826,881			1,619,488
	Allowance for uncompensated care	993,881			841,754
	Net trade accounts receivable	750,126			624,516
	Other receivables, net	358			897
	Net accounts receivable — Corporation	750,484			625,413
	Other receivables, net — adjustment for Holding	—			(269		)
	Net accounts receivable — Holding	$	750,484		$	625,144

	Other receivables primarily represent EmCare hospital subsidies and fees, and AMR fees for stand-by and special events and subsidies from community organizations.

	Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. In addition, a look-back analysis is done, typically after 15 months, to compare actual cash collected on a date of service basis to the revenue recorded for that period. Any adjustment necessary for an overage or deficit in these allowances based on actual collections is recorded through a revenue adjustment in the current period.

	AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated on claim level, historical write-off experience.

Business Combinations	'
	Business Combinations

	Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

Revenue Recognition	'
	Revenue Recognition

	Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients, for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies and fees at EmCare and fees for stand-by, special event and community subsidies at AMR.

	The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for the costs of the services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within our care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

	Net revenue for the three and nine month periods ended September 30, 2013 and 2012 consisted of the following:

		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Fee-for-service revenue, net of contractuals:
	Medicare	$	231,042		$	195,111		$	700,823		$	577,311
	Medicaid	51,991			47,723			155,055			141,050
	Commercial insurance and managed care	590,924			541,542			1,719,642			1,559,170
	Self-pay	645,774			611,508			1,964,068			1,703,304
	Sub-total	1,519,731			1,395,884			4,539,588			3,980,835
	Subsidies and fees	171,477			133,256			446,673			400,226
	Revenue, net of contractuals	1,691,208			1,529,140			4,986,261			4,381,061
	Provision for uncompensated care	(735,320		)	(708,329		)	(2,242,794		)	(1,952,858		)
	Net revenue	$	955,888		$	820,811		$	2,743,467		$	2,428,203

	Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate resulted in an increase of $1.1 million and a reduction of $1.6 million to the contractual discount or uncompensated care provisions for the three months ended September 30, 2013 and 2012, respectively, and an increase of $0.2 million and a reduction of $6.3 million to the contractual discount or uncompensated care provisions for the nine months ended September 30, 2013 and 2012, respectively.

	The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.

Financial Instruments and Concentration of Credit Risk	'
	Financial Instruments and Concentration of Credit Risk

	The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, other than current portion of self-insurance estimates, long-term debt and long-term liabilities, other than self-insurance estimates, constitute financial instruments. Based on management’s estimates, the carrying value of these financial instruments approximates their fair value as of September 30, 2013 and December 31, 2012. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2013, the Company derived approximately 28% of its revenue from Medicare and Medicaid, 68% from insurance providers and contracted payors, and 4% directly from patients.

	The Company estimates the fair value of its fixed rate senior subordinated notes based on quoted market prices (Level 1). The estimated fair value of the senior subordinated notes at September 30, 2013 was approximately $1,029.1 million with a carrying value of $950.0 million. EMCA Insurance Company, Ltd. held $15 million of the senior subordinated notes at September 30, 2013.

Fair Value Measurement	'
	Fair Value Measurement

	The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

	Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

	Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

	Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include fixed income mortgage backed securities, corporate bonds, and derivatives.

	Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

	The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2013 and December 31, 2012:

		September 30, 2013												December 31, 2012
	Description	Level 1			Level 2			Level 3			Total			Level 1		Level 2		Level 3		Total
	Assets:
	Securities	$	18,053		$	517		$	—		$	18,570		$	22,870	$	788	$	—	$	23,658
	Fuel hedge	$	—		$	538		$	—		$	538		$	—	$	631	$	—	$	631
	Liabilities:
	Contingent consideration	$	—		$	—		$	9,401		$	9,401		$	—	$	—	$	4,401	$	4,401
	Interest rate swap	$	—		$	3,453		$	—		$	3,453		$	—	$	4,586	$	—	$	4,586

	The contingent consideration balance classified as a Level 3 liability has increased by $5.0 million since December 31, 2012 due to recent acquisitions.

	During the nine months ended September 30, 2013, we had no transfers in and out of Level 1 and Level 2 fair value measurements.

Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements

	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”) to provide explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. ASU 2013-11 requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except if such a deferred tax asset is unavailable at the reporting date. If a deferred tax asset is unavailable at the reporting date, then the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 31, 2013. We do not expect the adoption of ASU 2013-11 to have a material impact on our financial position or results of operations.

	In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”) to improve the reporting of reclassifications out of accumulated other comprehensive income (“AOCI”).

	ASU 2013-02 requires the following:

	· present separately for each component of other comprehensive income, current period reclassifications out of AOCI and other amounts of current-period other comprehensive income; and

	· separately provide information about the effects on net income of significant amounts reclassified out of each component of AOCI if those amounts all are required to be reclassified to net income in their entirety in the same reporting period.

	The Company adopted this new guidance effective January 1, 2013 by adding disclosure in Note 8, Changes in Accumulated Other Comprehensive Income by Component.

Corporation	'
Equity Structure	'
Equity Structure	'
	Equity Structure — Corporation

	On February 13, 2011, Corporation entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Envision Healthcare Intermediate Corporation (“Parent”), formerly known as CDRT Acquisition Corporation, and CDRT Merger Sub, Inc. (“Merger Sub”), formerly a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, Merger Sub merged with and into Corporation, with Corporation as the surviving corporation and a wholly owned subsidiary of Parent on May 25, 2011. Immediately following the Merger, all of the outstanding common stock of Parent was owned by Holding, which is owned by affiliates of CD&R and members of management and directors of Corporation.

	Prior to the Merger, Corporation acted as the general partner and majority equity holder of EMS LP, with the balance of the EMS LP equity held by persons affiliated with Corporation’s previous principal equity holder. The EMS LP equity was exchangeable at any time for shares of Corporation’s common stock, and holders of the LP exchangeable units had the right to vote at stockholder meetings with limited exceptions. Accordingly, prior to the Merger, Corporation accounted for the LP exchangeable units as if the LP exchangeable units were shares of its common stock, including reporting the LP exchangeable units in the equity section of Corporation’s balance sheet and including the number of outstanding LP exchangeable units in both its basic and diluted earnings per share calculations.

	On May 25, 2011, in connection with the Merger, the equity structure of Holding was altered as follows:

	· LP units of the entity formerly known as EMS LP were exchanged for Corporation common stock;

	· outstanding shares of Corporation common stock were converted into the right to receive $6.88 per share in cash, without interest and less any applicable withholding taxes;

	· options to purchase shares of Corporation common stock (other than options that were rolled over by certain members of management as described below), vested or unvested, were cancelled and each option was converted into the right to receive a cash payment equal to the excess (if any) of $6.88 per share over the exercise price per share of the option times the number of shares subject to the option, without interest and less any applicable withholding taxes;

	· restricted shares, vested or unvested, were fully vested at the effective time and canceled and extinguished and each restricted share was converted into the right to receive $6.88 per share in cash, without interest and less any applicable withholding taxes;

	· restricted stock units, vested or unvested, were cancelled and extinguished, and each restricted stock unit was converted into the right to receive a cash payment equal to $6.88 per share times the number of shares of Corporation common stock subject to such restricted stock units, without interest and less any applicable withholding taxes;

	· investment funds (the “CD&R Affiliates”) sponsored by, or affiliated with, CD&R invested $887.1 million in the common stock of Holding, the proceeds of which were contributed to Parent, and the remainder of the acquisition consideration for the Merger was funded through a variety of debt instruments;

	· certain members of our management rolled over existing options to purchase Corporation common stock with an aggregate value of $28.3 million, based on the Merger consideration price, into options to purchase common stock of Holding; and

	· Merger Sub merged with and into Corporation, with Corporation as the surviving corporation.

Holding	'
Equity Structure	'
Equity Structure	'
	Equity Structure and Initial Public Offering — Holding

	On August 13, 2013, Holding’s Registration Statement was declared effective by the SEC for an initial public offering of its Common Stock. Holding registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock, which were sold to the underwriters pursuant to their option to purchase additional shares at a price of $23 per share. On August 19, 2013, Holding completed the offering of 48,300,000 shares of Common Stock, at a price of $23 per share, for an aggregate offering price of $1,110.9 million. At the closing, we received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with Holding and Corporation (“Consulting Agreement”) which was recorded to “Selling, general and administrative expenses” in the Company’s Consolidated Statements of Operation, see Note 12. As of September 30, 2013, approximately $1.6 million of these expenses have not been paid.

	Net proceeds from the initial public offering were used to (i) redeem in full Holding’s Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, and (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings. The remaining proceeds will be used for general corporate purposes which may include, among other things, repayment of indebtedness and acquisitions.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2013
Summary of Significant Accounting Policies	'
Schedule of accounts receivable and allowances	'

		September 30,			December 31,
		2013			2012
	Gross trade accounts receivable	$	3,570,888		$	3,085,758
	Allowance for contractual discounts	1,826,881			1,619,488
	Allowance for uncompensated care	993,881			841,754
	Net trade accounts receivable	750,126			624,516
	Other receivables, net	358			897
	Net accounts receivable — Corporation	750,484			625,413
	Other receivables, net — adjustment for Holding	—			(269		)
	Net accounts receivable — Holding	$	750,484		$	625,144

Schedule of net revenue	'

		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Fee-for-service revenue, net of contractuals:
	Medicare	$	231,042		$	195,111		$	700,823		$	577,311
	Medicaid	51,991			47,723			155,055			141,050
	Commercial insurance and managed care	590,924			541,542			1,719,642			1,559,170
	Self-pay	645,774			611,508			1,964,068			1,703,304
	Sub-total	1,519,731			1,395,884			4,539,588			3,980,835
	Subsidies and fees	171,477			133,256			446,673			400,226
	Revenue, net of contractuals	1,691,208			1,529,140			4,986,261			4,381,061
	Provision for uncompensated care	(735,320		)	(708,329		)	(2,242,794		)	(1,952,858		)
	Net revenue	$	955,888		$	820,811		$	2,743,467		$	2,428,203

Summary of the valuation of the Company's financial instruments by the fair value hierarchy levels	'

		September 30, 2013												December 31, 2012
	Description	Level 1			Level 2			Level 3			Total			Level 1		Level 2		Level 3		Total
	Assets:
	Securities	$	18,053		$	517		$	—		$	18,570		$	22,870	$	788	$	—	$	23,658
	Fuel hedge	$	—		$	538		$	—		$	538		$	—	$	631	$	—	$	631
	Liabilities:
	Contingent consideration	$	—		$	—		$	9,401		$	9,401		$	—	$	—	$	4,401	$	4,401
	Interest rate swap	$	—		$	3,453		$	—		$	3,453		$	—	$	4,586	$	—	$	4,586

Basic_and_Diluted_Net_Loss_Inc1

Basic and Diluted Net (Loss) Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Basic and Diluted Net (Loss) Income Per Share	'
EPS amounts and the basic and diluted weighted-average shares outstanding used in the calculation	'

		Quarter ended					Nine months ended
		September 30,					September 30,
		2013			2012		2013			2012
	Net (loss) income	$	(7,663	)	$	15,209	$	(1,913	)	$	28,842

	Weighted-average common shares outstanding — common stock:
	Basic	157,282,885			130,230,634		139,969,940			130,219,651
	Dilutive impact of stock awards outstanding	—			3,233,248		—			2,260,170
	Diluted	157,282,885			133,463,882		139,969,940			132,479,821

	Earnings per share — common stock:
	Basic net (loss) income per common share	$	(0.05	)	$	0.12	$	(0.01	)	$	0.22
	Diluted net (loss) income per common share	$	(0.05	)	$	0.11	$	(0.01	)	$	0.22

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities	'
Schedule of accrued liabilities	'

		September 30,			December 31,
		2013			2012
	Accrued wages and benefits	$	156,950		$	136,334
	Accrued paid time-off	27,267			25,626
	Current portion of self-insurance reserves	47,902			49,224
	Accrued restructuring	6,504			12,318
	Current portion of compliance and legal	6,166			3,711
	Accrued billing and collection fees	3,263			4,945
	Accrued incentive compensation	20,249			22,274
	Accrued interest	27,660			7,889
	Accrued income taxes	30,114			19,487
	Accrued dissenting shareholder settlement	—			41,826
	Other	56,643			63,796
	Total accrued liabilities — Corporation	$	382,718		$	387,430
	Adjustments for Holding:
	Accrued interest	—			10,406
	Accrued income taxes	(30,114		)	(8,901		)
	Total accrued liabilities — Holding	$	352,604		$	388,935

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Long-Term Debt	'
Schedule of long-term debt and capital leases	'

		September 30,			December 31,
		2013			2012
	Senior subordinated unsecured notes due 2019	$	950,000		$	950,000
	Senior subordinated unsecured notes purchased by the Company’s subsidiary	(15,000		)	(15,000		)
	Senior secured term loan due 2018 (4.00% at September 30, 2013)	1,301,475			1,160,609
	ABL Facility	—			125,000
	Notes due at various dates from 2013 to 2022 with interest rates from 6% to 10%	861			1,149
	Capital lease obligations due at various dates from 2013 to 2018	387			447
		2,237,723			2,222,205
	Less current portion	(12,316		)	(12,282		)
	Total long-term debt — Corporation	$	2,225,407		$	2,209,923
	Senior PIK Toggle Notes due 2017	—			437,175
	Total long-term debt — Holding	$	2,225,407		$	2,647,098

Changes_in_Accumulated_Other_C1

Changes in Accumulated Other Comprehensive Income by Component (Tables)	9 Months Ended
	Sep. 30, 2013
Changes in Accumulated Other Comprehensive Income by Component	'
Summary of changes in the Company's AOCI by component, after tax	'

		Fuel hedge			Interest rate swap			Unrealized			Total
								holding gains on
								available-for-sale
								securities
	Balance as of December 31, 2012	$	1,057		$	(2,861	)	$	1,591		$	(213	)
	Other comprehensive income before reclassifications	(546		)	(222		)	(410		)	(1,178		)
	Amounts reclassified from accumulated other comprehensive income	(203		)	929			(172		)	554
	Net current-period other comprehensive income	(749		)	707			(582		)	(624		)
	Balance as of September 30, 2013	$	308		$	(2,154	)	$	1,009		$	(837	)

Schedule of Consolidated Statement of Operations affected by reclassifications out of AOCI	'

		Amount reclassified from AOCI
		Quarter ended			Nine months ended			Affected line item on the
		September 30,			September 30,			Affected line item on the
	Details about AOCI components	2013			2013			Statement of Operations
	Gains and losses on cash flow hedges
	Fuel hedge	$	106		$	326		Operating expenses
	Interest rate swap	(502		)	(1,489		)	Interest expense
		(396		)	(1,163		)	Total before tax
		149			437			Tax benefit
		$	(247	)	$	(726	)	Net of tax

	Unrealized holding gains on available-for-sale securities	$	158		$	276		Realized gain on investments
		158			276			Total before tax
		(59		)	(104		)	Tax expense
		$	99		$	172		Net of tax

Restructuring_Charges_Tables

Restructuring Charges (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring Charges	'
Schedule of restructuring charges	'

		2012 Plan
		Lease & Other			Severance			Total
		Contract
		Termination Costs
	Balance as of December 31, 2012	$	6,295		$	4,058		$	10,353
	Incurred	1,885			3,107			4,992
	Paid	(5,902		)	(4,064		)	(9,966		)
	Balance as of September 30, 2013	$	2,278		$	3,101		$	5,379

Variable_Interest_Entities_Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2013
Variable Interest Entities	'
Summary of the HCA-EmCare JV assets and liabilities which are included in the consolidated financial statements	'

		September 30,		December 31,
		2013		2012
	Current assets	$	67,238,293	$	33,141,502
	Current liabilities	46,290,990		20,081,084

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Information	'
Schedule of the Company's operating segment results	'

		Quarter ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Facility-Based Physician Services
	Net revenue	$	605,105		$	485,936		$	1,729,158		$	1,403,792
	Segment Adjusted EBITDA	82,032			68,750			218,767			189,231
	Medical Transportation Services
	Net revenue	350,783			334,875			1,014,309			1,024,411
	Segment Adjusted EBITDA	39,623			34,690			109,843			102,105
	Total
	Total net revenue	955,888			820,811			2,743,467			2,428,203
	Total Segment Adjusted EBITDA — Corporation	121,655			103,440			328,610			291,336
	Other operating income (expenses) — Holding	15			—			(73		)	—
	Total Segment Adjusted EBITDA — Holding	121,670			103,440			328,537			291,336
	Reconciliation of Adjusted EBITDA to Net Income
	Segment Adjusted EBITDA — Corporation	$	121,655		$	103,440		$	328,610		$	291,336
	Depreciation and amortization expense	(35,175		)	(30,592		)	(104,552		)	(91,844		)
	Restructuring charges	(1,319		)	(2,028		)	(4,988		)	(10,751		)
	Equity-based compensation expense	(1,062		)	(1,062		)	(3,186		)	(3,186		)
	Related party management fees	(20,609		)	(1,250		)	(23,109		)	(3,750		)
	Interest expense	(39,131		)	(41,322		)	(117,959		)	(126,288		)
	Realized gain on investments	158			5			276			366
	Interest and other (expense) income	(52		)	937			(13,022		)	1,340
	Loss on early debt extinguishment	—			(1,561		)	(122		)	(6,733		)
	Income tax expense	(9,816		)	(11,448		)	(27,782		)	(21,952		)
	Equity in earnings of unconsolidated subsidiary	68			90			230			304
	Net income — Corporation	$	14,717		$	15,209		$	34,396		$	28,842
	Adjustments for Holding:
	Other operating income (expenses)	15			—			(73		)	—
	Loss on early debt extinguishment	(29,519		)	—			(29,519		)	—
	Interest expense	(7,641		)	—			(30,567		)	—
	Income tax benefit	14,765			—			23,850			—
	Net (loss) income — Holding	$	(7,663	)	$	15,209		$	(1,913	)	$	28,842

Schedule of reconciliation of Segment Adjusted EBITDA to cash flows provided by operating activities	'

		Quarter ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Segment Adjusted EBITDA — Corporation	$	121,655		$	103,440		$	328,610		$	291,336
	Related party management fees	(20,609		)	(1,250		)	(23,109		)	(3,750		)
	Restructuring charges	(1,319		)	(2,028		)	(4,988		)	(10,751		)
	Interest expense (less deferred loan fee amortization)	(35,303		)	(37,328		)	(106,644		)	(113,923		)
	Payment of dissenting shareholder settlement	—			—			(13,717		)	—
	Change in accounts receivable	(69,716		)	(25,547		)	(126,237		)	(68,376		)
	Change in other operating assets/liabilities	65,738			36,606			51,038			51,474
	Excess tax benefits from equity-based compensation	—			—			(3,168		)	—
	Interest and other income (expense)	(52		)	937			(13,022		)	1,340
	Income tax benefit (expense), net of change in deferred taxes	(9,729		)	31,491			(25,538		)	21,194
	Other	89			(205		)	775			703
	Cash flows provided by operating activities - Corporation	$	50,754		$	106,116		$	64,000		$	169,247
	Adjustments for Holding:
	Other operating income (expenses)	15			—			(73		)	—
	Interest expense (less deferred loan fee amortization)	(6,936		)	—			(27,749		)	—
	Change in accounts receivable	(1,827		)	—			(269		)	—
	Change in other operating assets/liabilities	(25,050		)	—			(36,209		)	—
	Income tax benefit, net of change in deferred taxes	14,766			—			25,925			—
	Cash flows provided by operating activities — Holding	$	31,722		$	106,116		$	25,625		$	169,247

Guarantors_of_Debt_Tables

Guarantors of Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Guarantors of Debt	'
Schedule of Consolidating Statements of Operations	'
	Consolidating Statements of Operations

			For the three months ended September 30, 2013
						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Net revenue		$	—		$	955,403		$	19,415		$	(18,930	)	$	955,888
	Compensation and benefits		—			677,618			179			—			677,797
	Operating expenses		—			110,396			8			—			110,404
	Insurance expense		—			30,841			15,063			(18,930		)	26,974
	Selling, general and administrative expenses		—			40,714			17			—			40,731
	Depreciation and amortization expense		—			35,171			4			—			35,175
	Restructuring charges		—			1,319			—			—			1,319
	Income from operations		—			59,344			4,144			—			63,488
	Interest (loss) income from restricted assets		—			2			—			—			2
	Interest expense		—			(39,131		)	—			—			(39,131		)
	Realized (loss) gain on investments		—			158			—			—			158
	Interest and other expense		—			(6		)	(46		)	—			(52		)
	Income before taxes and equity in earnings of unconsolidated subsidiary		—			20,367			4,098			—			24,465
	Income tax expense		—			(9,811		)	(5		)	—			(9,816		)
	Income before equity in earnings of unconsolidated subsidiary		—			10,556			4,093			—			14,649
	Equity in earnings of unconsolidated subsidiary		14,717			—			68			(14,717		)	68
	Net income (loss)		$	14,717		$	10,556		$	4,161		$	(14,717	)	$	14,717

			For the three months ended September 30, 2012
						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Net revenue		$	—		$	820,352		$	18,708		$	(18,249	)	$	820,811
	Compensation and benefits		—			577,347			155			—			577,502
	Operating expenses		—			100,609			8			—			100,617
	Insurance expense		—			21,187			19,969			(18,249		)	22,907
	Selling, general and administrative expenses		—			18,534			7			—			18,541
	Depreciation and amortization expense		—			30,592			—			—			30,592
	Restructuring charges		—			2,028			—			—			2,028
	Income from operations		—			70,055			(1,431		)	—			68,624
	Interest income from restricted assets		—			(1,817		)	1,701			—			(116		)
	Interest expense		—			(41,322		)	—			—			(41,322		)
	Realized gain on investments		—			(1		)	6			—			5
	Interest and other income		—			973			(36		)	—			937
	Loss on early debt extinguishment		—			(1,561		)	—			—			(1,561		)
	Income before taxes and equity in earnings of unconsolidated subsidiary		—			26,327			240			—			26,567
	Income tax expense		—			(11,443		)	(5		)	—			(11,448		)
	Income before equity in earnings of unconsolidated subsidiary		—			14,884			235			—			15,119
	Equity in earnings of unconsolidated subsidiary		15,209			—			90			(15,209		)	90
	Net income (loss)		$	15,209		$	14,884		$	325		$	(15,209	)	$	15,209

			For the nine months ended September 30, 2013
						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Net revenue		$	—		$	2,742,003		$	57,024		$	(55,560	)	$	2,743,467
	Compensation and benefits		—			1,963,022			524			—			1,963,546
	Operating expenses		—			313,055			20			—			313,075
	Insurance expense		—			78,623			55,584			(55,560		)	78,647
	Selling, general and administrative expenses		—			86,476			42			—			86,518
	Depreciation and amortization expense		—			104,538			14			—			104,552
	Restructuring charges		—			4,988			—			—			4,988
	Income from operations		—			191,301			840			—			192,141
	Interest (loss) income from restricted assets		—			(3,002		)	3,636			—			634
	Interest expense		—			(117,959		)	—			—			(117,959		)
	Realized (loss) gain on investments		—			37			239			—			276
	Interest and other expense		—			(12,913		)	(109		)	—			(13,022		)
	Loss on early debt extinguishment		—			(122		)	—			—			(122		)
	Income before taxes and equity in earnings of unconsolidated subsidiary		—			57,342			4,606			—			61,948
	Income tax expense		—			(27,765		)	(17		)	—			(27,782		)
Income before equity in earnings of unconsolidated subsidiary		—			29,577			4,589			—			34,166
Equity in earnings of unconsolidated subsidiary		34,396			—			230			(34,396		)	230
Net income (loss)		$	34,396		$	29,577		$	4,819		$	(34,396	)	$	34,396

		For the nine months ended September 30, 2012
					Subsidiary			Subsidiary			Eliminations/
		Corporation			Guarantors			Non-Guarantor			Adjustments			Total
Net revenue		$	—		$	2,426,835		$	56,650		$	(55,282	)	$	2,428,203
Compensation and benefits		—			1,705,758			447			—			1,706,205
Operating expenses		—			304,991			14			—			305,005
Insurance expense		—			70,435			60,199			(55,282		)	75,352
Selling, general and administrative expenses		—			57,655			15			—			57,670
Depreciation and amortization expense		—			91,844			—			—			91,844
Restructuring charges		—			10,751			—			—			10,751
Income from operations		—			185,401			(4,025		)	—			181,376
Interest income from restricted assets		—			(2,908		)	3,337			—			429
Interest expense		—			(126,288		)	—			—			(126,288		)
Realized gain on investments		—			(1,176		)	1,542			—			366
Interest and other income (expense)		—			1,463			(123		)	—			1,340
Loss on early debt extinguishment		—			(6,733		)	—			—			(6,733		)
Income before taxes and equity in earnings of unconsolidated subsidiary		—			49,759			731			—			50,490
Income tax expense		—			(21,937		)	(15		)	—			(21,952		)
Income before equity in earnings of unconsolidated subsidiary		—			27,822			716			—			28,538
Equity in earnings of unconsolidated subsidiary		28,842			—			304			(28,842		)	304
Net income (loss)		$	28,842		$	27,822		$	1,020		$	(28,842	)	$	28,842

Schedule of Consolidating Balance Sheet	'
	Consolidating Balance Sheet
	As of September 30, 2013

						Subsidiary			Subsidiary			Eliminations/
			Corporation			Guarantors			Non-Guarantor			Adjustments			Total
	Assets
	Current assets:
	Cash and cash equivalents		$	—		$	52,624		$	56,415		$	(15,000	)	$	94,039
	Insurance collateral		—			9,431			73,500			(53,892		)	29,039
	Trade and other accounts receivable, net		—			748,544			3,614			(1,674		)	750,484
	Parts and supplies inventory		—			22,526			13			—			22,539
	Prepaids and other current assets		4,323			23,628			452			—			28,403
	Current deferred tax assets		—			—			3,515			(3,515		)	—
	Current assets		4,323			856,753			137,509			(74,081		)	924,504
	Non-current assets:
	Property, plant, and equipment, net		—			190,837			—			—			190,837
	Intercompany receivable		2,253,808			—			10,383			(2,264,191		)	—
	Intangible assets, net		—			524,317			—			—			524,317
	Non-current deferred tax assets		—			—			3,125			(3,125		)	—
	Insurance collateral		—			72,015			12,107			(72,015		)	12,107
	Goodwill		—			2,440,476			125			(2,981		)	2,437,620
	Other long-term assets		66,753			—			1,252			7,964			75,969
	Investment and advances in subsidiaries		1,033,139			4,379			6,998			(1,044,516		)	—
	Assets		$	3,358,023		$	4,088,777		$	171,499		$	(3,452,945	)	$	4,165,354
	Liabilities and Equity
	Current liabilities:
	Accounts payable		$	—		$	65,107		$	134		$	—		$	65,241
	Accrued liabilities		30,657			340,355			15,093			(3,387		)	382,718
	Current deferred tax liabilities		—			31,741			—			(3,515		)	28,226
	Current portion of long-term debt		11,872			444			—			—			12,316
	Current liabilities		42,529			437,647			15,227			(6,902		)	488,501
	Long-term debt		2,239,604			803			—			(15,000		)	2,225,407
	Long-term deferred tax liabilities		—			161,970			—			(5,120		)	156,850
	Insurance reserves and other long-term liabilities		—			184,497			151,893			(124,214		)	212,176
	Intercompany payable		—			2,264,191			—			(2,264,191		)	—
	Liabilities		2,282,133			3,049,108			167,120			(2,415,427		)	3,082,934
	Equity:
	Common stock		—			—			30			(30		)	—
	Treasury stock		(1,347		)	—			—			—			(1,347		)
	Additional paid-in capital		1,003,013			963,264			—			(963,264		)	1,003,013
	Retained earnings		75,061			71,925			3,136			(75,061		)	75,061
	Accumulated other comprehensive loss		(837		)	(2,050		)	1,213			837			(837		)
	Total Corporation equity		1,075,890			1,033,139			4,379			(1,037,518		)	1,075,890
	Noncontrolling interest		—			6,530			—			—			6,530
	Total equity		1,075,890			1,039,669			1,243			(1,037,518		)	1,082,420
	Liabilities and Equity		$	3,358,023		$	4,088,777		$	171,499		$	(3,452,945	)	$	4,165,354

	Consolidating Balance Sheet
	As of December 31, 2012

			Corporation			Subsidiary			Subsidiary			Eliminations/			Total
						Guarantors			Non-			Adjustments
									Guarantor
	Assets
	Current assets:
	Cash and cash equivalents		$	—		$	6,924		$	65,627		$	(15,000	)	$	57,551
	Insurance collateral		—			6,626			35,975			(18,120		)	24,481
	Trade and other accounts receivable, net		—			623,651			3,738			(1,976		)	625,413
	Parts and supplies inventory		—			22,041			9			—			22,050
	Prepaids and other current assets		—			23,679			297			(462		)	23,514
	Current deferred tax assets		—			—			3,447			(3,447		)	—
	Current assets		—			682,921			109,093			(39,005		)	753,009
	Non-current assets:
Property, plant, and equipment, net		—			191,864			—			—			191,864
Intercompany receivable		2,237,508			—			11,596			(2,249,104		)	—
Intangible assets, net		—			564,218			—			—			564,218
Non-current deferred tax assets		—			—			1,097			(1,097		)	—
Insurance collateral		—			65,762			5,491			(50,493		)	20,760
Goodwill		—			2,416,613			—			(2,981		)	2,413,632
Other long-term assets		84,538			—			1,580			(261		)	85,857
Investment and advances in subsidiaries		930,119			3,001			—			(933,120		)	—
Assets		$	3,252,165		$	3,924,379		$	128,857		$	(3,276,061	)	$	4,029,340
Liabilities and Equity
Current liabilities:
Accounts payable		$	—		$	53,505		$	287		—			$	53,792
Accrued liabilities		47,184			328,153			15,782			(3,689		)	387,430
Current deferred tax liabilities		—			27,015			—			(3,447		)	23,568
Current portion of long-term debt		11,871			411			—			—			12,282
Current liabilities		59,055			409,084			16,069			(7,136		)	477,072
Long-term debt		2,223,738			1,185			—			(15,000		)	2,209,923
Long-term deferred tax liabilities		—			159,942			—			(3,092		)	156,850
Insurance reserves and other long-term liabilities		—			168,415			109,787			(68,609		)	209,593
Intercompany payable		—			2,249,104			—			(2,249,104		)	—
Liabilities		2,282,793			2,987,730			125,856			(2,342,941		)	3,053,438
Equity:
Common stock		—			—			30			(30		)	—
Treasury stock		(381		)	—			—			—			(381		)
Additional paid-in capital		908,488			871,306			—			(871,306		)	908,488
Retained earnings		61,478			59,206			2,272			(61,478		)	61,478
Accumulated other comprehensive loss		(213		)	(393		)	699			(306		)	(213		)
Total Corporation equity		969,372			930,119			3,001			(933,120		)	969,372
Noncontrolling interest		—			6,530			—			—			6,530
Total equity		969,372			936,649			3,001			(933,120		)	975,902
Liabilities and Equity		$	3,252,165		$	3,924,379		$	128,857		$	(3,276,061	)	$	4,029,340

Schedule of Condensed Consolidating Statement of Cash Flows	'
	Condensed Consolidating Statement of Cash Flows

			For the nine months ended September 30, 2013
						Subsidiary			Subsidiary
			Corporation			Guarantors			Non-guarantors			Total
	Cash Flows from Operating Activities
	Net cash provided by (used in) operating activities		$	—		$	91,441		$	(34,489	)	$	56,952
	Cash Flows from Investing Activities
	Purchase of property, plant and equipment		—			(45,493		)	—			(45,493		)
	Proceeds from sale of property, plant and equipment		—			396			—			396
	Acquisition of businesses, net of cash received		—			(27,358		)	—			(27,358		)
	Net change in insurance collateral		—			(24,102		)	26,982			2,880
	Other investing activities		—			(456		)	—			(456		)
	Net cash (used in) provided by investing activities		—			(97,013		)	26,982			(70,031		)
	Cash Flows from Financing Activities
	Corporation issuance of class A common stock		1,117			—			—			1,117
	Borrowings under senior secured term loan facility		150,000			—			—			150,000
	Capital contributed by Holding		85,073			—			—			85,073
	Repayments of senior secured term loan facility and other debt		(10,383		)	—			—			(10,383		)
	Net payments under ABL credit facility		—			(125,000		)	—			(125,000		)
	Debt issue costs		(5,007		)	—			—			(5,007		)
	Excess tax benefits from stock-based compensation		—			3,168			—			3,168
	Dividend paid		—			(20,813		)	—			(20,813		)
	Payment of dissenting shareholder settlement		—			(38,336		)	—			(38,336		)
	Net change in bank overdrafts		—			1,686			—			1,686
	Net intercompany borrowings (payments)		(220,800		)	222,505			(1,705		)	—
	Net cash (used in) provided by financing activities		—			43,210			(1,705		)	41,505
	Change in cash and cash equivalents		—			37,638			(9,212		)	28,426
	Cash and cash equivalents, beginning of period		—			6,925			50,626			57,551
	Cash and cash equivalents, end of period		$	—		$	44,563		$	41,414		$	85,977

			For the nine months ended September 30, 2012
						Subsidiary			Subsidiary
			Corporation			Guarantors			Non-guarantors			Total
	Cash Flows from Operating Activities
	Net cash provided by (used in) operating activities		$	—		$	223,882		$	(54,635	)	$	169,247
	Cash Flows from Investing Activities
	Purchase of property, plant and equipment		—			(44,311		)	—			(44,311		)
	Proceeds from sale of property, plant and equipment		—			7,092			—			7,092
	Acquisition of businesses, net of cash received		—			(20,559		)	—			(20,559		)
	Net change in insurance collateral		—			(33,717		)	124,318			90,601
	Other investing activities		—			589			—			589
	Net cash (used in) provided by investing activities		—			(90,906		)	124,318			33,412
	Cash Flows from Financing Activities
	Repayments of debt and capital lease obligations		(225,616		)	—			—			(225,616		)
	Debt issue costs		(95		)	—			—			(95		)
	Repayment of equity		(528		)	—			—			(528		)
	Proceeds from noncontrolling interest		—			6,530			—			6,530
	Net change in bank overdrafts		—			11,455			—			11,455
	Net intercompany borrowings (payments)		226,239			(199,043		)	(27,196		)	—
	Net cash used in financing activities		—			(181,058		)	(27,196		)	(208,254		)
	Change in cash and cash equivalents		—			(48,082		)	42,487			(5,595		)
	Cash and cash equivalents, beginning of period		—			104,657			29,366			134,023
	Cash and cash equivalents, end of period		$	—		$	56,575		$	71,853		$	128,428

General_Details

General (Details) (USD $)	9 Months Ended		0 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Jul. 29, 2013	Aug. 13, 2013
	item	Dec. 31, 2012	Holding	Holding
Basis of Presentation of Financial Statements	'	'	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01	'	$0.01
Stock split ratio	'	'	9.3	'
Shares of common stock issued	'	'	132,082,885	'
Treasury shares issued	'	'	504,197	'
Number of operating subsidiaries	2	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Insurance	'	'	'	'	'
Reinsurance receivable	$1.30	'	$1.30	'	$1.60
Discount rate for claims other than general liability claims (as a percent)	'	'	1.50%	'	'
Increases in provisions for insurance liabilities for prior year losses	1.6	0.9	1.2	0.3	'
Long-term portion of insurance reserves	192.8	'	192.8	'	189.4
Minimum	'	'	'	'	'
Insurance	'	'	'	'	'
Liability exposure in instances where third-party insurance coverage is obtained	'	'	1	'	'
Maximum	'	'	'	'	'
Insurance	'	'	'	'	'
Liability exposure in instances where third-party insurance coverage is obtained	'	'	$3	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Trade and Other Accounts Receivable, net	'	'
Net accounts receivable	$750,484	$625,144
Period after which look-back analysis is performed to review and adjust overage or deficit in accounts receivable allowances	'15 months	'
Holding	'	'
Trade and Other Accounts Receivable, net	'	'
Other receivables, net	'	-269
Corporation	'	'
Trade and Other Accounts Receivable, net	'	'
Gross trade accounts receivable	3,570,888	3,085,758
Allowance for contractual discounts	1,826,881	1,619,488
Allowance for uncompensated care	993,881	841,754
Net trade accounts receivable	750,126	624,516
Other receivables, net	358	897
Net accounts receivable	$750,484	$625,413
EmCare	'	'
Trade and Other Accounts Receivable, net	'	'
Provision for uncompensated care associated with fee for service charges as a percentage of outstanding self-pay receivables	'	97.00%
AMR	'	'
Trade and Other Accounts Receivable, net	'	'
Provision for uncompensated care associated with fee for service charges as a percentage of outstanding self-pay receivables	'	93.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractuals	$1,519,731,000	$1,395,884,000	$4,539,588,000	$3,980,835,000
Subsidies and fees	171,477,000	133,256,000	446,673,000	400,226,000
Revenue, net of contractuals	1,691,208,000	1,529,140,000	4,986,261,000	4,381,061,000
Provision for uncompensated care	-735,320,000	-708,329,000	-2,242,794,000	-1,952,858,000
Net revenue	955,888,000	820,811,000	2,743,467,000	2,428,203,000
Revenue Recognition	'	'	'	'
Increase (decrease) in contractual discount or uncompensated care provisions	1,100,000	-1,600,000	200,000	-6,300,000
Medicare	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractuals	231,042,000	195,111,000	700,823,000	577,311,000
Medicaid	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractuals	51,991,000	47,723,000	155,055,000	141,050,000
Commercial insurance and managed care	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractuals	590,924,000	541,542,000	1,719,642,000	1,559,170,000
Self-pay	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractuals	$645,774,000	$611,508,000	$1,964,068,000	$1,703,304,000
Minimum \| Self-pay	'	'	'	'
Revenue Recognition	'	'	'	'
Treatment period	'	'	'30 days	'
Bills and notifications period	'	'	'90 days	'
Maximum \| Self-pay	'	'	'	'
Revenue Recognition	'	'	'	'
Treatment period	'	'	'60 days	'
Bills and notifications period	'	'	'120 days	'

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

0 Months Ended

Sep. 30, 2013

25-May-11

Sep. 30, 2013

31-May-11

Sep. 30, 2013

31-May-11

Sep. 30, 2013

Aug. 19, 2013

Aug. 13, 2013

Aug. 19, 2013

Aug. 13, 2013

Corporation

CD&R

Holding

Stock options

Restricted shares

Restricted stock units

Corporation

Senior PIK Toggle Notes due 2017

Revolving credit facility

CD&R

Initial public offering

Underwriters overallotment option

Equity Structure

Shares of Common Stock issued

48,300,000

42,000,000

6,300,000

Issue price (in dollars per share)

$23

Aggregate offering price

$1,110,900,000

$1,112,017,000

$1,117,000

$1,025,900,000

$1,110,900,000

Underwriters' discounts and commissions and offering expenses

85,000,000

Payment made in connection with the termination of a corporation consulting agreement

20,000,000

Remaining stock issuance costs payable

1,600,000

Amount used to redeem or repay the debt outstanding

479,600,000

16,500,000

Cash to be received for outstanding shares of common stock (in dollars per share)

$6.88

Price per share to determine cash payment (in dollars per share)

$6.88

Cash to be received for stock awards (in dollars per share)

$6.88

Investment in common stock

887,100,000

Aggregate value of existing options rolled over to purchase common stock

$28,300,000

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 5) (Net revenue, Customer concentration risk)	9 Months Ended
	Sep. 30, 2013
Medicare and Medicaid	'
Concentration of credit risk	'
Percentage of concentration risk	28.00%
Insurance providers and contracted payors	'
Concentration of credit risk	'
Percentage of concentration risk	68.00%
Patients	'
Concentration of credit risk	'
Percentage of concentration risk	4.00%

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 6) (Senior subordinated unsecured notes purchased by EVHC subsidiary, USD $)	Sep. 30, 2013
In Millions, unless otherwise specified	Sep. 30, 2013
Financial Instruments	'
Estimated fair value of the senior subordinate notes	$1,029.10
Carrying value of the senior subordinate notes	950
EMCA Insurance Company, Ltd.	'
Financial Instruments	'
Carrying value of the senior subordinate notes	$15

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details 7) (USD $)	12 Months Ended
	Dec. 31, 2012	Sep. 30, 2013
Fair value measurement	'	'
Transfers in assets from Level 1 to level 2 fair value measurements	'	$0
Transfers in assets from Level 2 to level 1 fair value measurements	'	0
Transfers in liabilities from Level 1 to level 2 fair value measurements	'	0
Transfers in liabilities from Level 2 to level 1 fair value measurements	'	0
Level 1 \| Securities	'	'
Fair value measurement	'	'
Assets	22,870,000	18,053,000
Level 2 \| Securities	'	'
Fair value measurement	'	'
Assets	788,000	517,000
Level 2 \| Fuel hedge	'	'
Fair value measurement	'	'
Assets	631,000	538,000
Level 2 \| Interest rate swap	'	'
Fair value measurement	'	'
Liabilities	4,586,000	3,453,000
Level 3 \| Contingent consideration	'	'
Fair value measurement	'	'
Liabilities	4,401,000	9,401,000
Increase in a level 3 liability of the contingent consideration	5,000,000	'
Total \| Securities	'	'
Fair value measurement	'	'
Assets	23,658,000	18,570,000
Total \| Fuel hedge	'	'
Fair value measurement	'	'
Assets	631,000	538,000
Total \| Contingent consideration	'	'
Fair value measurement	'	'
Liabilities	4,401,000	9,401,000
Total \| Interest rate swap	'	'
Fair value measurement	'	'
Liabilities	$4,586,000	$3,453,000

Basic_and_Diluted_Net_Loss_Inc2

Basic and Diluted Net (Loss) Income Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Basic and diluted net (loss) income per share	'	'	'	'
Net (loss) income	($7,663)	$15,209	($1,913)	$28,842
Weighted-average common shares outstanding - common stock:	'	'	'	'
Basic (in shares)	157,282,885	130,230,634	139,969,940	130,219,651
Diluted (in shares)	157,282,885	133,463,882	139,969,940	132,479,821
Earnings per share - common stock:	'	'	'	'
Basic net (loss) income per common share (in dollars per share)	($0.05)	$0.12	($0.01)	$0.22
Diluted net (loss) income per common share (in dollars per share)	($0.05)	$0.11	($0.01)	$0.22
Holding	'	'	'	'
Basic and diluted net (loss) income per share	'	'	'	'
Net (loss) income	($7,663)	$15,209	($1,913)	$28,842
Weighted-average common shares outstanding - common stock:	'	'	'	'
Basic (in shares)	157,282,885	130,230,634	139,969,940	130,219,651
Dilutive impact of stock awards outstanding (in shares)	'	3,233,248	'	2,260,170
Diluted (in shares)	157,282,885	133,463,882	139,969,940	132,479,821
Earnings per share - common stock:	'	'	'	'
Basic net (loss) income per common share (in dollars per share)	($0.05)	$0.12	($0.01)	$0.22
Diluted net (loss) income per common share (in dollars per share)	($0.05)	$0.11	($0.01)	$0.22
Stock awards of common stock outstanding excluded from the computations of diluted loss per share and weighted-average common shares outstanding	6,088,252	'	8,663,107	0

Acquisitions_Details

Acquisitions (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Millions, unless otherwise specified		CMORx, LLC	Guardian	NightRays
		item
Acquisitions	'	'	'	'
Number of related corporations which leverage the provision of non-emergency medical transportation services	'	2	'	'
Purchase price	'	$26.40	'	'
Goodwill	'	24.4	'	'
Intangible assets	'	3.9	'	'
Property, plant and equipment	'	1.6	'	'
Net current liabilities	'	3.5	'	'
Amount reclassified from goodwill to intangible assets	'	'	8.7	4.3
Increase in deferred tax liability	$3.30	'	'	'

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Accrued liabilities	'	'
Total accrued liabilities	$352,604	$388,935
Holding	'	'
Accrued liabilities	'	'
Accrued interest	'	10,406
Accrued income taxes	-30,114	-8,901
Corporation	'	'
Accrued liabilities	'	'
Accrued wages and benefits	156,950	136,334
Accrued paid time-off	27,267	25,626
Current portion of self-insurance reserves	47,902	49,224
Accrued restructuring	6,504	12,318
Current portion of compliance and legal	6,166	3,711
Accrued billing and collection fees	3,263	4,945
Accrued incentive compensation	20,249	22,274
Accrued interest	27,660	7,889
Accrued income taxes	30,114	19,487
Accrued dissenting shareholder settlement	'	41,826
Other	56,643	63,796
Total accrued liabilities	$382,718	$387,430

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

In Thousands, unless otherwise specified

Senior subordinated unsecured notes purchased by the Company's subsidiary

Senior secured term loan due 2018

Notes due at various dates from 2013 to 2022

Holding

Corporation

Senior PIK Toggle Notes due 2017

Senior subordinated unsecured notes due 2019

Senior subordinated unsecured notes purchased by the Company's subsidiary

Senior secured term loan due 2018

ABL Facility

Notes due at various dates from 2013 to 2022

Capital lease obligations due at various dates from 2013 to 2018

Long-Term Debt

Amount of debt held

$15,000

$2,237,723

$2,222,205

$950,000

($15,000)

$1,301,475

$1,160,609

$125,000

$861

$1,149

$387

$447

Less current portion

-12,316

-12,282

-12,316

-12,282

Total long-term debt

$2,225,407

$2,647,098

$2,225,407

$2,647,098

$437,175

$2,225,407

$2,209,923

Interest rate (as a percent)

8.13%

4.00%

Interest rate, minimum (as a percent)

6.00%

Interest rate, maximum (as a percent)

10.00%

Term of debt

'7 years

'5 years

LongTerm_Debt_Details_2

Long-Term Debt (Details 2) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Jun. 30, 2012

Aug. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Feb. 07, 2013

Sep. 30, 2013

Dec. 31, 2012

Feb. 07, 2013

Feb. 27, 2013

Dec. 31, 2012

Feb. 27, 2013

Sep. 30, 2013

Dec. 31, 2012

Holding

Term Loan Facility

Senior subordinated unsecured notes purchased by the Company's subsidiary

Senior PIK Toggle Notes due 2017

Corporation

Holding

Term Loan Facility

ABL Facility

Senior subordinated unsecured notes purchased by the Company's subsidiary

Option one

Option two

Option one

Option two

Adjusted LIBOR rate

Overnight federal funds rate

Adjusted LIBOR rate

Overnight federal funds rate

Adjusted LIBOR rate

Average daily excess availability less than or equal to 33% of availability

Average daily excess availability greater than 33% but less than or equal to 66% of availability

Average daily excess availability greater than 66% of availability

Average daily excess availability less than or equal to 33% of availability

Average daily excess availability greater than 33% but less than or equal to 66% of availability

Average daily excess availability greater than 66% of availability

Maximum

Minimum

Maximum

Minimum

Maximum

Minimum

Maximum

Minimum

Long-Term Debt

Incremental borrowings

$150,000,000

Reference rate (as a percent)

1.00%

2.00%

Interest rate margin (as a percent)

3.00%

2.00%

0.50%

1.00%

2.00%

1.75%

1.50%

0.50%

1.00%

0.75%

0.50%

Interest rate in the event of meeting specified consolidated first lien net leverage ratio (as a percent)

2.75%

1.75%

Consolidated first lien net leverage ratio

2.5

Variable interest rate basis

'LIBOR

'one-month LIBOR rate

'LIBOR

'one-month LIBOR rate

Maximum borrowing capacity

450,000,000

Average daily excess availability as a percentage of availability

33.00%

66.00%

33.00%

66.00%

Amount of debt held

15,000,000

2,237,723,000

2,222,205,000

1,301,475,000

1,160,609,000

125,000,000

-15,000,000

Repayments of debt and capital lease obligations

3,339,000

53,142,000

10,383,000

225,616,000

17,200,000

3,339,000

53,142,000

10,383,000

225,616,000

Unamortized debt issuance costs written-off

100,000

Debt issuance expense related to amendments

5,011,000

95,000

5,007,000

95,000

Redemption price of debt instrument as a percentage of principal amount

102.75%

Loss on early debt extinguishment

($29,519,000)

($1,561,000)

($29,641,000)

($6,733,000)

($29,519,000)

$29,500,000

($1,561,000)

($122,000)

($6,733,000)

Interest rate (as a percent)

4.00%

8.13%

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
	gal		agreement
			gal
Derivative Instruments and Hedging Activities	'	'	'	'	'
Payments made or received under hedge agreements	'	'	'	$0	'
Fuel hedge	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Number of master agreements	'	'	1	'	'
Total gallons of diesel fuel	3,400,000	'	3,400,000	'	'
Gallons of diesel fuel as a percentage of total estimated annual usage	27.20%	'	27.20%	'	'
Fair value of derivative asset	0.5	'	0.5	'	0.6
Net receipts from the counterparty	0.1	0	0.4	0.8	'
Period over which deferred gain (loss) is expected to be reclassified from AOCI	'	'	'12 months	'	'
Amount of deferred gain (loss) expected to be reclassified from AOCI	'	'	0.4	'	'
Fuel hedge \| Minimum	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Diesel fuel price (in dollars per gallon)	3.65	'	3.65	'	'
Fuel hedge \| Maximum	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Diesel fuel price (in dollars per gallon)	4.02	'	4.02	'	'
Interest rate swap agreements	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Period over which deferred gain (loss) is expected to be reclassified from AOCI	'	'	'12 months	'	'
Amount of deferred gain (loss) expected to be reclassified from AOCI	'	'	-2	'	'
Notional amount of debt obligations	400	'	400	'	'
Effective rate of interest of debt (as a percent)	4.49%	'	4.49%	'	'
Minimum variable interest rate of debt (as a percent)	1.00%	'	1.00%	'	'
Fair value of derivative liability	3.5	'	3.5	'	4.6
Net payments to the counterparty	$0.50	'	$1.50	'	'

Changes_in_Accumulated_Other_C2

Changes in Accumulated Other Comprehensive Income by Component (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Changes in the company's AOCI by component, after tax	'
Balance at the beginning of the period	($213)
Other comprehensive income before reclassifications	-1,178
Amounts reclassified from accumulated other comprehensive income	554
Net current-period other comprehensive income	-624
Balance at the end of the period	-837
Unrealized holding gains on available-for-sale securities	'
Changes in the company's AOCI by component, after tax	'
Balance at the beginning of the period	1,591
Other comprehensive income before reclassifications	-410
Amounts reclassified from accumulated other comprehensive income	-172
Net current-period other comprehensive income	-582
Balance at the end of the period	1,009
Fuel hedge \| Gains and losses on cash flow hedges	'
Changes in the company's AOCI by component, after tax	'
Balance at the beginning of the period	1,057
Other comprehensive income before reclassifications	-546
Amounts reclassified from accumulated other comprehensive income	-203
Net current-period other comprehensive income	-749
Balance at the end of the period	308
Interest rate swap \| Gains and losses on cash flow hedges	'
Changes in the company's AOCI by component, after tax	'
Balance at the beginning of the period	-2,861
Other comprehensive income before reclassifications	-222
Amounts reclassified from accumulated other comprehensive income	929
Net current-period other comprehensive income	707
Balance at the end of the period	($2,154)

Changes_in_Accumulated_Other_C3

Changes in Accumulated Other Comprehensive Income by Component (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Operating expenses	$110,387	$100,617	$313,145	$305,005
Interest expense	46,772	41,322	148,526	126,288
Realized gain on investments	158	5	276	366
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	-12,680	26,567	1,789	50,490
Tax (expense) benefit	4,949	-11,448	-3,932	-21,952
Net (loss) income	-7,663	15,209	-1,913	28,842
Gains and losses on cash flow hedges \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	-396	'	-1,163	'
Tax (expense) benefit	149	'	437	'
Net (loss) income	-247	'	-726	'
Gains and losses on cash flow hedges \| Fuel hedge \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Operating expenses	106	'	326	'
Gains and losses on cash flow hedges \| Interest rate swap \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Interest expense	-502	'	-1,489	'
Unrealized holding gains on available-for-sale securities \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Realized gain on investments	158	'	276	'
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	158	'	276	'
Tax (expense) benefit	-59	'	-104	'
Net (loss) income	$99	'	$172	'

Restructuring_Charges_Details

Restructuring Charges (Details) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
					2012 Plan	2012 Plan	Lease & Other Contract Termination Cost	Lease & Other Contract Termination Cost	Severance	Severance
							2012 Plan	2012 Plan	2012 Plan	2012 Plan
Restructuring Charges	'	'	'	'	'	'	'	'	'	'
Incurred	$1,319	$2,028	$4,988	$10,751	$4,992	'	$1,885	'	$3,107	'
Paid	'	'	'	'	-9,966	'	-5,902	'	-4,064	'
Accrued restructuring liability	'	'	'	'	$5,379	$10,353	$2,278	$6,295	$3,101	$4,058

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	9 Months Ended			23 Months Ended	0 Months Ended	1 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Apr. 15, 2013	Mar. 10, 2010	Sep. 12, 2006	Sep. 30, 2006	31-May-11	20-May-11
		Merion Capital, L.P	Merion Capital, L.P	AMR	Violation of the federal anti-kickback statute	Violation of the federal anti-kickback statute	Subpoena from the DOJ	Subpoena from the DOJ
				Predecessor	AMR	AMR	AMR	AMR
				item	Predecessor	Predecessor		Predecessor
Commitments and Contingencies	'	'	'	'	'	'	'	'
Amount paid for settlement	'	'	'	'	$9,000,000	'	'	'
Term of CIA	'	'	'	'	'	'5 years	'5 years	'
Settlement amount to resolve the claims	'	'	52,100,000	'	'	'	'	2,700,000
Payment of dissenting shareholder settlement	13,717,000	13,700,000	'	'	'	'	'	'
Payment of dissenting shareholder settlement	38,336,000	38,300,000	'	'	'	'	'	'
Number of lawsuits purporting to be class actions filed	'	'	'	4	'	'	'	'
Legal settlement costs	'	8,400,000	'	'	'	'	'	'
Accrued interest included in reserve for unpaid merger consideration	'	$1,900,000	'	'	'	'	'	'

Equity_Based_Compensation_Deta

Equity Based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Oct. 31, 2012

Sep. 30, 2013

Stock Compensation Plan

Omnibus Incentive Plan

Holding

Stock options

RSUs

Key management employees

Maximum

Market price of $6.88 per share

Market price of $8.60 per share

Market price of $5.41 per share

Market price of $7.85 per share

Market price of $23.00 per share

Non-employee directors

Equity based compensation

Strike price (in dollars per share)

$3.69

Strike price before revision (in dollars per share)

$6.88

Term of awards

'10 years

Compensation charges

$1,062,000

$3,186,000

$1,100,000

$3,200,000

Number of shares granted

36,679

7,328

25,052

9,214

641

Market price (in dollars per share)

$6.88

$8.60

$5.41

$7.85

$23

Fair market value of awards to be granted

$100,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
Related Party Transactions (Details) (USD $)	Apr. 02, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Corporation	'	'	'	'	'
Related party transactions	'	'	'	'	'
Annual management fee	'	$20,609,000	$1,250,000	$23,109,000	$3,750,000
Dividend declared and paid	20,800,000	'	'	'	'
Corporation \| Holding	'	'	'	'	'
Related party transactions	'	'	'	'	'
IPO proceeds distribution to subsidiary	'	86,100,000	'	'	'
CD&R	'	'	'	'	'
Related party transactions	'	'	'	'	'
Annual fee	'	'	'	5,000,000	'
Annual management fee	'	20,600,000	1,300,000	23,100,000	3,800,000
Payment made in connection with the termination of a consulting agreement	'	$20,000,000	'	'	'

Variable_Interest_Entities_Det

Variable Interest Entities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	EmCare	HCA-EmCare JV	HCA-EmCare JV
Variable Interest Entities	'	'	'	'	'
Voting control (as a percent)	'	'	50.00%	'	'
Summary of the assets and liabilities which are included in the Company's consolidated financial statements	'	'	'	'	'
Current assets	$1,409,100	$753,259	'	$67,238,293	$33,141,502
Current liabilities	$458,504	$478,694	'	$46,290,990	$20,081,084

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
	Sep. 30, 2013	Sep. 30, 2012	item	Sep. 30, 2012
Segment Information	'	'	'	'
Number of separately managed business units	'	'	2	'
Segment Information	'	'	'	'
Net revenue	$955,888	$820,811	$2,743,467	$2,428,203
Segment Adjusted EBITDA	121,670	103,440	328,537	291,336
Reconciliation of Adjusted EBITDA to Net Income	'	'	'	'
Segment Adjusted EBITDA	121,670	103,440	328,537	291,336
Depreciation and amortization expense	-35,175	-30,592	-104,552	-91,844
Restructuring charges	-1,319	-2,028	-4,988	-10,751
Equity-based compensation expense	-1,062	-1,062	-3,186	-3,186
Interest expense	-46,772	-41,322	-148,526	-126,288
Realized gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	-29,519	-1,561	-29,641	-6,733
Income tax benefit (expense)	4,949	-11,448	-3,932	-21,952
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	-7,663	15,209	-1,913	28,842
Holding	'	'	'	'
Segment Information	'	'	'	'
Other operating income (expenses)	15	'	-73	'
Reconciliation of Adjusted EBITDA to Net Income	'	'	'	'
Interest expense	-7,641	'	-30,567	'
Other operating income (expenses)	15	'	-73	'
Loss on early debt extinguishment	-29,519	'	-29,519	'
Income tax benefit (expense)	14,765	'	23,850	'
Net (loss) income	-7,663	15,209	-1,913	28,842
Corporation	'	'	'	'
Segment Information	'	'	'	'
Net revenue	955,888	820,811	2,743,467	2,428,203
Segment Adjusted EBITDA	121,655	103,440	328,610	291,336
Reconciliation of Adjusted EBITDA to Net Income	'	'	'	'
Segment Adjusted EBITDA	121,655	103,440	328,610	291,336
Depreciation and amortization expense	-35,175	-30,592	-104,552	-91,844
Restructuring charges	-1,319	-2,028	-4,988	-10,751
Equity-based compensation expense	-1,062	-1,062	-3,186	-3,186
Related party management fees	-20,609	-1,250	-23,109	-3,750
Interest expense	-39,131	-41,322	-117,959	-126,288
Realized gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	'	-1,561	-122	-6,733
Income tax benefit (expense)	-9,816	-11,448	-27,782	-21,952
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	14,717	15,209	34,396	28,842
Segment \| Corporation	'	'	'	'
Segment Information	'	'	'	'
Net revenue	955,888	820,811	2,743,467	2,428,203
Segment Adjusted EBITDA	121,655	103,440	328,610	291,336
Reconciliation of Adjusted EBITDA to Net Income	'	'	'	'
Segment Adjusted EBITDA	121,655	103,440	328,610	291,336
Facility-based physician services \| Corporation	'	'	'	'
Segment Information	'	'	'	'
Net revenue	605,105	485,936	1,729,158	1,403,792
Segment Adjusted EBITDA	82,032	68,750	218,767	189,231
Reconciliation of Adjusted EBITDA to Net Income	'	'	'	'
Segment Adjusted EBITDA	82,032	68,750	218,767	189,231
Medical transportation services \| Corporation	'	'	'	'
Segment Information	'	'	'	'
Net revenue	350,783	334,875	1,014,309	1,024,411
Segment Adjusted EBITDA	39,623	34,690	109,843	102,105
Reconciliation of Adjusted EBITDA to Net Income	'	'	'	'
Segment Adjusted EBITDA	$39,623	$34,690	$109,843	$102,105

Segment_Information_Details_2

Segment Information (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Reconciliation of Segment Adjusted EBITDA to cash flows provided by (used in) operating activities	'	'	'	'
Segment Adjusted EBITDA	$121,670	$103,440	$328,537	$291,336
Restructuring charges	-1,319	-2,028	-4,988	-10,751
Payment of dissenting shareholder settlement	'	'	-13,717	'
Change in accounts receivable	-71,543	-25,547	-126,506	-68,376
Excess tax benefits from equity-based compensation	'	'	-3,168	'
Interest and other (expense) income	-52	937	-13,022	1,340
Net cash provided by operating activities	31,722	106,116	25,625	169,247
Holding	'	'	'	'
Reconciliation of Segment Adjusted EBITDA to cash flows provided by (used in) operating activities	'	'	'	'
Other operating income (expenses)	15	'	-73	'
Interest expense (less deferred loan fee amortization)	-6,936	'	-27,749	'
Change in accounts receivable	-1,827	'	-269	'
Change in other operating assets/liabilities	-25,050	'	-36,209	'
Income tax benefit (expense), net of change in deferred taxes	14,766	'	25,925	'
Corporation	'	'	'	'
Reconciliation of Segment Adjusted EBITDA to cash flows provided by (used in) operating activities	'	'	'	'
Segment Adjusted EBITDA	121,655	103,440	328,610	291,336
Related party management fees	-20,609	-1,250	-23,109	-3,750
Restructuring charges	-1,319	-2,028	-4,988	-10,751
Interest expense (less deferred loan fee amortization)	-35,303	-37,328	-106,644	-113,923
Payment of dissenting shareholder settlement	'	'	-13,717	'
Change in accounts receivable	-69,716	-25,547	-126,237	-68,376
Change in other operating assets/liabilities	65,738	36,606	51,038	51,474
Excess tax benefits from equity-based compensation	'	'	-3,168	'
Interest and other (expense) income	-52	937	-13,022	1,340
Income tax benefit (expense), net of change in deferred taxes	-9,729	31,491	-25,538	21,194
Other	89	-205	775	703
Net cash provided by operating activities	$50,754	$106,116	$64,000	$169,247

Guarantors_of_Debt_Details

Guarantors of Debt (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidating Statements of Operations	'	'	'	'
Net revenue	$955,888	$820,811	$2,743,467	$2,428,203
Compensation and benefits	677,797	577,502	1,963,546	1,706,205
Operating expenses	110,387	100,617	313,145	305,005
Insurance expense	26,974	22,907	78,647	75,352
Selling, general and administrative expenses	40,733	18,541	86,521	57,670
Depreciation and amortization expense	35,175	30,592	104,552	91,844
Restructuring charges	1,319	2,028	4,988	10,751
Income from operations	63,503	68,624	192,068	181,376
Interest (loss) income from restricted assets	2	-116	634	429
Interest expense	-46,772	-41,322	-148,526	-126,288
Realized (loss) gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	-29,519	-1,561	-29,641	-6,733
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	-12,680	26,567	1,789	50,490
Income tax benefit (expense)	4,949	-11,448	-3,932	-21,952
(Loss) income before equity in earnings of unconsolidated subsidiary	-7,731	15,119	-2,143	28,538
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	-7,663	15,209	-1,913	28,842
Corporation	'	'	'	'
Consolidating Statements of Operations	'	'	'	'
Net revenue	955,888	820,811	2,743,467	2,428,203
Compensation and benefits	677,797	577,502	1,963,546	1,706,205
Operating expenses	110,404	100,617	313,075	305,005
Insurance expense	26,974	22,907	78,647	75,352
Selling, general and administrative expenses	40,731	18,541	86,518	57,670
Depreciation and amortization expense	35,175	30,592	104,552	91,844
Restructuring charges	1,319	2,028	4,988	10,751
Income from operations	63,488	68,624	192,141	181,376
Interest (loss) income from restricted assets	2	-116	634	429
Interest expense	-39,131	-41,322	-117,959	-126,288
Realized (loss) gain on investments	158	5	276	366
Interest and other (expense) income	-52	937	-13,022	1,340
Loss on early debt extinguishment	'	-1,561	-122	-6,733
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	24,465	26,567	61,948	50,490
Income tax benefit (expense)	-9,816	-11,448	-27,782	-21,952
(Loss) income before equity in earnings of unconsolidated subsidiary	14,649	15,119	34,166	28,538
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	14,717	15,209	34,396	28,842
Subsidiary Guarantors	'	'	'	'
Consolidating Statements of Operations	'	'	'	'
Net revenue	955,403	820,352	2,742,003	2,426,835
Compensation and benefits	677,618	577,347	1,963,022	1,705,758
Operating expenses	110,396	100,609	313,055	304,991
Insurance expense	30,841	21,187	78,623	70,435
Selling, general and administrative expenses	40,714	18,534	86,476	57,655
Depreciation and amortization expense	35,171	30,592	104,538	91,844
Restructuring charges	1,319	2,028	4,988	10,751
Income from operations	59,344	70,055	191,301	185,401
Interest (loss) income from restricted assets	2	-1,817	-3,002	-2,908
Interest expense	-39,131	-41,322	-117,959	-126,288
Realized (loss) gain on investments	158	-1	37	-1,176
Interest and other (expense) income	-6	973	-12,913	1,463
Loss on early debt extinguishment	'	-1,561	-122	-6,733
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	20,367	26,327	57,342	49,759
Income tax benefit (expense)	-9,811	-11,443	-27,765	-21,937
(Loss) income before equity in earnings of unconsolidated subsidiary	10,556	14,884	29,577	27,822
Net (loss) income	10,556	14,884	29,577	27,822
Subsidiary Non-guarantors	'	'	'	'
Consolidating Statements of Operations	'	'	'	'
Net revenue	19,415	18,708	57,024	56,650
Compensation and benefits	179	155	524	447
Operating expenses	8	8	20	14
Insurance expense	15,063	19,969	55,584	60,199
Selling, general and administrative expenses	17	7	42	15
Depreciation and amortization expense	4	'	14	'
Income from operations	4,144	-1,431	840	-4,025
Interest (loss) income from restricted assets	'	1,701	3,636	3,337
Realized (loss) gain on investments	'	6	239	1,542
Interest and other (expense) income	-46	-36	-109	-123
(Loss) income before income taxes, and equity in earnings of unconsolidated subsidiary	4,098	240	4,606	731
Income tax benefit (expense)	-5	-5	-17	-15
(Loss) income before equity in earnings of unconsolidated subsidiary	4,093	235	4,589	716
Equity in earnings of unconsolidated subsidiary	68	90	230	304
Net (loss) income	4,161	325	4,819	1,020
Eliminations/Adjustments	'	'	'	'
Consolidating Statements of Operations	'	'	'	'
Net revenue	-18,930	-18,249	-55,560	-55,282
Insurance expense	-18,930	-18,249	-55,560	-55,282
Equity in earnings of unconsolidated subsidiary	-14,717	-15,209	-34,396	-28,842
Net (loss) income	($14,717)	($15,209)	($34,396)	($28,842)

Guarantors_of_Debt_Details_2

Guarantors of Debt (Details 2) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	$575,761	$37,032	$57,832	$128,428	$124,198	$134,023
Insurance collateral	29,039	'	24,481	'	'	'
Trade and other accounts receivable, net	750,484	'	625,144	'	'	'
Parts and supplies inventory	22,539	'	22,050	'	'	'
Prepaids and other current assets	31,277	'	23,752	'	'	'
Total current assets	1,409,100	'	753,259	'	'	'
Non-current assets:	'	'	'	'	'	'
Property, plant and equipment, net	190,837	'	191,864	'	'	'
Intangible assets, net	524,317	'	564,218	'	'	'
Insurance collateral	12,107	'	20,760	'	'	'
Goodwill	2,437,620	'	2,413,632	'	'	'
Other long-term assets	75,969	'	93,100	'	'	'
Total assets	4,649,950	'	4,036,833	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	65,358	'	53,909	'	'	'
Accrued liabilities	352,604	'	388,935	'	'	'
Current deferred tax liabilities	28,226	'	23,568	'	'	'
Current portion of long-term debt	12,316	'	12,282	'	'	'
Total current liabilities	458,504	'	478,694	'	'	'
Long-term debt	2,225,407	'	2,647,098	'	'	'
Long-term deferred tax liabilities	156,761	'	156,761	'	'	'
Insurance reserves and other long-term liabilities	212,176	'	209,593	'	'	'
Total liabilities	3,052,848	'	3,492,146	'	'	'
Equity:	'	'	'	'	'	'
Common stock	1,804	'	1,307	'	'	'
Treasury stock	-1,347	'	-381	'	'	'
Additional paid-in capital	1,580,519	'	525,098	'	'	'
Retained earnings	10,433	'	12,346	'	'	'
Accumulated other comprehensive loss	-837	'	-213	'	'	'
Total stockholders' equity	1,590,572	'	538,157	'	'	'
Noncontrolling interest	6,530	'	6,530	'	'	'
Total equity	1,597,102	'	544,687	'	'	'
Total liabilities and equity	4,649,950	'	4,036,833	'	'	'
Corporation	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	94,039	36,752	57,551	128,428	124,198	134,023
Insurance collateral	29,039	'	24,481	'	'	'
Trade and other accounts receivable, net	750,484	'	625,413	'	'	'
Parts and supplies inventory	22,539	'	22,050	'	'	'
Prepaids and other current assets	28,403	'	23,514	'	'	'
Total current assets	924,504	'	753,009	'	'	'
Non-current assets:	'	'	'	'	'	'
Property, plant and equipment, net	190,837	'	191,864	'	'	'
Intercompany receivable	2,253,808	'	2,237,508	'	'	'
Intangible assets, net	524,317	'	564,218	'	'	'
Insurance collateral	12,107	'	20,760	'	'	'
Goodwill	2,437,620	'	2,413,632	'	'	'
Other long-term assets	75,969	'	85,857	'	'	'
Investment and advances in subsidiaries	1,033,139	'	930,119	'	'	'
Total assets	4,165,354	'	4,029,340	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	65,241	'	53,792	'	'	'
Accrued liabilities	382,718	'	387,430	'	'	'
Current deferred tax liabilities	28,226	'	23,568	'	'	'
Current portion of long-term debt	12,316	'	12,282	'	'	'
Total current liabilities	488,501	'	477,072	'	'	'
Long-term debt	2,225,407	'	2,209,923	'	'	'
Long-term deferred tax liabilities	156,850	'	156,850	'	'	'
Insurance reserves and other long-term liabilities	212,176	'	209,593	'	'	'
Total liabilities	3,082,934	'	3,053,438	'	'	'
Equity:	'	'	'	'	'	'
Common stock	'	'	'	'	'	'
Treasury stock	-1,347	'	-381	'	'	'
Additional paid-in capital	1,003,013	'	908,488	'	'	'
Retained earnings	75,061	'	61,478	'	'	'
Accumulated other comprehensive loss	-837	'	-213	'	'	'
Total stockholders' equity	1,075,890	'	969,372	'	'	'
Noncontrolling interest	6,530	'	6,530	'	'	'
Total equity	1,082,420	'	975,902	'	'	'
Total liabilities and equity	4,165,354	'	4,029,340	'	'	'
Subsidiary Guarantors	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	52,624	'	6,924	'	'	'
Insurance collateral	9,431	'	6,626	'	'	'
Trade and other accounts receivable, net	748,544	'	623,651	'	'	'
Parts and supplies inventory	22,526	'	22,041	'	'	'
Prepaids and other current assets	23,628	'	23,679	'	'	'
Total current assets	856,753	'	682,921	'	'	'
Non-current assets:	'	'	'	'	'	'
Property, plant and equipment, net	190,837	'	191,864	'	'	'
Intangible assets, net	524,317	'	564,218	'	'	'
Insurance collateral	72,015	'	65,762	'	'	'
Goodwill	2,440,476	'	2,416,613	'	'	'
Investment and advances in subsidiaries	4,379	'	3,001	'	'	'
Total assets	4,088,777	'	3,924,379	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	65,107	'	53,505	'	'	'
Accrued liabilities	340,355	'	328,153	'	'	'
Current deferred tax liabilities	31,741	'	27,015	'	'	'
Current portion of long-term debt	444	'	411	'	'	'
Total current liabilities	437,647	'	409,084	'	'	'
Long-term debt	803	'	1,185	'	'	'
Long-term deferred tax liabilities	161,970	'	159,942	'	'	'
Insurance reserves and other long-term liabilities	184,497	'	168,415	'	'	'
Intercompany payable	2,264,191	'	2,249,104	'	'	'
Total liabilities	3,049,108	'	2,987,730	'	'	'
Equity:	'	'	'	'	'	'
Additional paid-in capital	963,264	'	871,306	'	'	'
Retained earnings	71,925	'	59,206	'	'	'
Accumulated other comprehensive loss	-2,050	'	-393	'	'	'
Total stockholders' equity	1,033,139	'	930,119	'	'	'
Noncontrolling interest	6,530	'	6,530	'	'	'
Total equity	1,039,669	'	936,649	'	'	'
Total liabilities and equity	4,088,777	'	3,924,379	'	'	'
Subsidiary Non-Guarantor	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	56,415	'	65,627	'	'	'
Insurance collateral	73,500	'	35,975	'	'	'
Trade and other accounts receivable, net	3,614	'	3,738	'	'	'
Parts and supplies inventory	13	'	9	'	'	'
Prepaids and other current assets	452	'	297	'	'	'
Current deferred tax assets	3,515	'	3,447	'	'	'
Total current assets	137,509	'	109,093	'	'	'
Non-current assets:	'	'	'	'	'	'
Intercompany receivable	10,383	'	11,596	'	'	'
Non-current deferred tax assets	3,125	'	1,097	'	'	'
Insurance collateral	12,107	'	5,491	'	'	'
Goodwill	125	'	'	'	'	'
Other long-term assets	1,252	'	1,580	'	'	'
Investment and advances in subsidiaries	6,998	'	'	'	'	'
Total assets	171,499	'	128,857	'	'	'
Current liabilities:	'	'	'	'	'	'
Accounts payable	134	'	287	'	'	'
Accrued liabilities	15,093	'	15,782	'	'	'
Total current liabilities	15,227	'	16,069	'	'	'
Insurance reserves and other long-term liabilities	151,893	'	109,787	'	'	'
Total liabilities	167,120	'	125,856	'	'	'
Equity:	'	'	'	'	'	'
Common stock	30	'	30	'	'	'
Retained earnings	3,136	'	2,272	'	'	'
Accumulated other comprehensive loss	1,213	'	699	'	'	'
Total stockholders' equity	4,379	'	3,001	'	'	'
Total equity	1,243	'	3,001	'	'	'
Total liabilities and equity	171,499	'	128,857	'	'	'
Eliminations/Adjustments	'	'	'	'	'	'
Current assets:	'	'	'	'	'	'
Cash and cash equivalents	-15,000	'	-15,000	'	'	'
Insurance collateral	-53,892	'	-18,120	'	'	'
Trade and other accounts receivable, net	-1,674	'	-1,976	'	'	'
Prepaids and other current assets	'	'	-462	'	'	'
Current deferred tax assets	-3,515	'	-3,447	'	'	'
Total current assets	-74,081	'	-39,005	'	'	'
Non-current assets:	'	'	'	'	'	'
Intercompany receivable	-2,264,191	'	-2,249,104	'	'	'
Non-current deferred tax assets	-3,125	'	-1,097	'	'	'
Insurance collateral	-72,015	'	-50,493	'	'	'
Goodwill	-2,981	'	-2,981	'	'	'
Other long-term assets	7,964	'	-261	'	'	'
Investment and advances in subsidiaries	-1,044,516	'	-933,120	'	'	'
Total assets	-3,452,945	'	-3,276,061	'	'	'
Current liabilities:	'	'	'	'	'	'
Accrued liabilities	-3,387	'	-3,689	'	'	'
Current deferred tax liabilities	-3,515	'	-3,447	'	'	'
Total current liabilities	-6,902	'	-7,136	'	'	'
Long-term debt	-15,000	'	-15,000	'	'	'
Long-term deferred tax liabilities	-5,120	'	-3,092	'	'	'
Insurance reserves and other long-term liabilities	-124,214	'	-68,609	'	'	'
Intercompany payable	-2,264,191	'	-2,249,104	'	'	'
Total liabilities	-2,415,427	'	-2,342,941	'	'	'
Equity:	'	'	'	'	'	'
Common stock	-30	'	-30	'	'	'
Additional paid-in capital	-963,264	'	-871,306	'	'	'
Retained earnings	-75,061	'	-61,478	'	'	'
Accumulated other comprehensive loss	837	'	-306	'	'	'
Total stockholders' equity	-1,037,518	'	-933,120	'	'	'
Total equity	-1,037,518	'	-933,120	'	'	'
Total liabilities and equity	($3,452,945)	'	($3,276,061)	'	'	'

Guarantors_of_Debt_Details_3

Guarantors of Debt (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Cash Flows from Operating Activities	'	'	'	'
Net cash provided by (used in) operating activities	$31,722	$106,116	$25,625	$169,247
Cash Flows from Investing Activities	'	'	'	'
Purchases of property, plant and equipment	-19,295	-19,126	-45,493	-44,311
Proceeds from sale of property, plant and equipment	68	5,641	396	7,092
Acquisition of businesses, net of cash received	-25,935	-19,259	-27,358	-20,559
Net change in insurance collateral	3,282	-17,773	2,880	90,601
Other investing activities	-404	2,885	-456	589
Net cash (used in) provided by investing activities	-42,284	-47,632	-70,031	33,412
Cash Flows from Financing Activities	'	'	'	'
Corporation issuance of class A common stock	1,110,900	'	1,112,017	'
Borrowings under senior secured term loan facility	'	'	150,000	'
Capital contributed by Holding	'	'	85,073	'
Repayments of senior secured term loan facility and other debt	-3,339	-53,142	-10,383	-225,616
Net payments under ABL credit facility	'	'	-125,000	'
Debt issue costs	'	'	-5,011	-95
Excess tax benefits from stock-based compensation	'	'	3,168	'
Payment of dissenting shareholder settlement	'	'	-38,336	'
Repayment of equity	'	-398	'	'
Proceeds from noncontrolling interest	'	'	'	6,530
Net change in bank overdrafts	-6,364	-714	1,686	11,455
Net cash provided by (used in) financing activities	549,291	-54,254	562,335	-208,254
Change in cash and cash equivalents	538,729	4,230	517,929	-5,595
Cash and cash equivalents, beginning of period	'	'	57,551	134,023
Cash and cash equivalents, end of period	85,977	128,428	85,977	128,428
Corporation	'	'	'	'
Cash Flows from Operating Activities	'	'	'	'
Net cash provided by (used in) operating activities	50,754	106,116	64,000	169,247
Cash Flows from Investing Activities	'	'	'	'
Purchases of property, plant and equipment	-19,295	-19,126	-45,493	-44,311
Proceeds from sale of property, plant and equipment	68	5,641	396	7,092
Acquisition of businesses, net of cash received	-25,935	-19,259	-27,358	-20,559
Net change in insurance collateral	3,282	-17,773	2,880	90,601
Other investing activities	-404	2,885	-456	589
Net cash (used in) provided by investing activities	-42,284	-47,632	-70,031	33,412
Cash Flows from Financing Activities	'	'	'	'
Corporation issuance of class A common stock	'	'	1,117	'
Borrowings under senior secured term loan facility	'	'	150,000	'
Capital contributed by Holding	'	'	85,073	'
Repayments of senior secured term loan facility and other debt	-3,339	-53,142	-10,383	-225,616
Net payments under ABL credit facility	-27,500	'	-125,000	'
Debt issue costs	'	'	-5,007	-95
Excess tax benefits from stock-based compensation	'	'	3,168	'
Dividend paid	'	'	-20,813	'
Payment of dissenting shareholder settlement	'	'	-38,336	'
Repayment of equity	'	-398	'	-528
Proceeds from noncontrolling interest	'	'	'	6,530
Net change in bank overdrafts	-6,431	-714	1,686	11,455
Net intercompany borrowings (payments)	'	'	-220,800	226,239
Net cash provided by (used in) financing activities	48,817	-54,254	42,519	-208,254
Change in cash and cash equivalents	57,287	4,230	36,488	-5,595
Subsidiary Guarantors	'	'	'	'
Cash Flows from Operating Activities	'	'	'	'
Net cash provided by (used in) operating activities	'	'	91,441	223,882
Cash Flows from Investing Activities	'	'	'	'
Purchases of property, plant and equipment	'	'	-45,493	-44,311
Proceeds from sale of property, plant and equipment	'	'	396	7,092
Acquisition of businesses, net of cash received	'	'	-27,358	-20,559
Net change in insurance collateral	'	'	-24,102	-33,717
Other investing activities	'	'	-456	589
Net cash (used in) provided by investing activities	'	'	-97,013	-90,906
Cash Flows from Financing Activities	'	'	'	'
Net payments under ABL credit facility	'	'	-125,000	'
Excess tax benefits from stock-based compensation	'	'	3,168	'
Dividend paid	'	'	-20,813	'
Payment of dissenting shareholder settlement	'	'	-38,336	'
Proceeds from noncontrolling interest	'	'	'	6,530
Net change in bank overdrafts	'	'	1,686	11,455
Net intercompany borrowings (payments)	'	'	222,505	-199,043
Net cash provided by (used in) financing activities	'	'	43,210	-181,058
Change in cash and cash equivalents	'	'	37,638	-48,082
Cash and cash equivalents, beginning of period	'	'	6,925	104,657
Cash and cash equivalents, end of period	44,563	56,575	44,563	56,575
Subsidiary Non-guarantors	'	'	'	'
Cash Flows from Operating Activities	'	'	'	'
Net cash provided by (used in) operating activities	'	'	-34,489	-54,635
Cash Flows from Investing Activities	'	'	'	'
Net change in insurance collateral	'	'	26,982	124,318
Net cash (used in) provided by investing activities	'	'	26,982	124,318
Cash Flows from Financing Activities	'	'	'	'
Net intercompany borrowings (payments)	'	'	-1,705	-27,196
Net cash provided by (used in) financing activities	'	'	-1,705	-27,196
Change in cash and cash equivalents	'	'	-9,212	42,487
Cash and cash equivalents, beginning of period	'	'	50,626	29,366
Cash and cash equivalents, end of period	$41,414	$71,853	$41,414	$71,853